세계의 의료 영상용 AI 시장(2025년) : 제1권 - 시장 분석과 예측, 제2권 - 기업 개요

World Market for AI in Medical Imaging 2025: Volume 1 - Market Analysis & Forecasts and Volume 2 - Company Briefs

US $ 4,950 ￦ 6,963,000

PDF (Individual License)

US $ 5,450 ￦ 7,666,000

PDF (Team License)

US $ 8,950 ￦ 12,589,000

PDF (Enterprise License)

한글목차

시장 현황

• 시장 규모 : 2023년 27억 달러 → 2032년 284억 달러(CAGR 29.9%).
• 성장 카탈리스트 : 기업을 위한 "AI 스토어"거래, NTAP & CADx CPT 코드, 중국 보조금, 방사선 기사 부족.
• 모달리티 구성 : CT와 MRI가 현재 지출의 60% 이상을 차지하고, 2028년 이후에는 초음파가 가속.
• 임상 리더 : 2028년까지 종양 AI가 신경학을 뽑아, 구조화 리포팅의 성숙에 따라 순환기가 3위로 약진.
• 지역 역학 : 아시아태평양의 성장률은 2027년 이후 유럽을 상회합니다.

주요 시장 동향, 지역 성장, 공급업체를 위한 전략적 의미

의료 영상의 영역에 AI의 통합은 실험적 호기심에서 주류의 필수 사항으로 변화하고 있습니다. 이 전환은 다양한 요인이 얽혀 진행되고 있습니다.

• 세계의 화상 진단 건수는 증가의 일도를 따르고 있으며, 추정에서는 매년 전 세계적으로 약 50억 건(모든 모달리티의 합계)의 화상 진단이 실시되고 있어, 특히 신흥 시장에서의 성장이 현저합니다.
• 규제 상황은 점점 더 적합합니다. 2023년 중반부터 후반 시점에서 FDA는 의료용으로 약 700개의 AI/ML 장비를 승인 또는 인가하고 있으며, 그 중 약 76%는 방사선과용입니다(진단, 방어, 워크플로 지원 도구 포함).
• 많은 의료 시스템에서 임상 수요가 공급을 능가하고 있으며 방사선 기사 부족이 AI 기반 워크 플로우 강화를위한 절호의 환경을 조성하고 있습니다.

이 생태계 내에서 Marketstrat는 AI 솔루션이 진단 정확도를 높이고 병태를 조기에 발견하는 것부터 대량 스캔 관리를 효율화하는 것까지 다면적인 과제를 다루고 있다고 보고 있습니다. 시장의 두 자리 CAGR 예측은 AI의 잠재력에 대한 진정한 낙관론과 특히 종양, 신경, 심혈관 영상에서 조기에 구체적인 임상 성공을 반영합니다.

지역 성장 패턴

가속하고 있지만 불균일

Marketstrat의 분석에 따르면 세계 CAGR은 30% 가까이 에 이르렀으며 시장은 2023년 27억 달러에서 2032년까지 284억 달러 로 성장합니다. 성장 촉진요인은

• 북미 - 최대 절대 상승 폭. 기업 규모의 플랫폼 거래, AI 지원 읽기에 대한 가치 기반의 상환, 완전 디지털 검출기 플릿으로의 교환 사이클의 가속이 채용을 뒷받침합니다.
• 아시아태평양 - 중국의 여러 해에 걸친 AI 보조금 프로그램, 일본의 새로운 CADx 상환 코드, 인도 및 ASEAN의 사설 네트워크에서의 급속한 롤아웃이 촉진요인이 되어, 북미에 이어 달러 기반으로 가장 급속하게 확대합니다.
• 유럽 -MDR 인증 알고리즘이 모달리티 업그레이드에 번들되어 암 검진의 국가 목표가 수요에 박차를 가하고 있기 때문에 견조한 성장을 보여줍니다.
• 라틴아메리카, 중동, 아프리카 - 작은 기반이면서 매력적인 포켓. 브라질 결핵/폐 AI에 대한 조건부 자금 지원과 사우디아라비아의 Vision 2030 이미징 구축이 선도 역할을 합니다.

공급업체의 전략적 의미

• 1. 포인트 솔루션보다 플랫폼 - IDN과 공공 시스템은 여러 알고리즘을 가진 "AI 스토어"계약을 맺는 것이 늘어나고 있으며, 폭이 넓고 입증된 사이버 보안을 가진 벤더가 유리해지고 있습니다.
• 2. 지역 규정 준수가 해자 - 유럽의 MDR과 중국의 CFDA/GB 기준은 기회적 진입을 제한하는 고비용 장벽이 됩니다.
• 3. 신흥 시장의 가격 결정력은 떨어진다 - 클라우드 퍼스트의 SaaS 번들과 OEM 내장의 라이선싱 모델이, 라틴아메리카, 중동 및 아프리카의 입찰의 필수 조건이 되고 있습니다.
• 4. 임상 워크플로의 통합은 결정적 - 최대 규모의 거래는 원활한 PACS/RIS 통합, 구조화된 보고서, AI 권장 사항에 대한 감사 추적에 달려 있습니다.

본 보고서에서는 세계의 의료 영상용 AI 시장에 대해 조사 분석하여 시장 규모의 추계, 이미징 모달리티 및 임상 응용 분야별 예측, 벤더 120사프로파일 등의 정보를 제공합니다.

목차

Vol.1 - 시장 분석 및 예측

섹션 1 - 주요 요약

섹션 2 - 조사 방법

섹션 3 - 전략적 시장 분석 및 프레임워크

• 이 장을 읽는 이유는?
• 전망(2025-2030년)
• 제안 : 스테이크홀더 유형별
• 섹션의 소개
• 세계 시장과 수술 건수 : 상황의 개요
• 시장 성장 촉진요인과 억제요인
• 세계 시장 예측 : 지역별(2023-2032년)
• Markintel M^3 Matrix(Market Momentum Matrix)
• Markintel Technology Evolution Matrix(TEM)
• Markintel TDIT(Technology Diffusion and Impact Timeline)
• Markintel Solution Adoption & Growth Matrix - 세계
• Markintel ARC Index(Approvals, Reimbursement, Clinical Validation)
• Markintel GTM Growth Maturity Matrix - 세계 시장
• 경쟁 데이터 세트 - AI 이미징 세계 시장
• 중요사항
• 성장과 성숙의 하이라이트(발췌)
• 경쟁 구도와 클러스터

섹션 4 - 세계 시장 분석 및 예측

• 섹션 개요
• 세계 시장 예측 : 지역별
• 세계 시장 분석 : 임상 분야별
• 세계의 종양 영상 AI 시장
• 세계의 심장 영상 AI 시장
• 세계의 신경 영상 AI 시장
• 세계의 호흡 영상 AI 시장
• 세계의 정형외과 및 MSK 영상 AI 시장
• 세계의 다른 임상 분야의 영상 AI 시장
• 세계 시장 분석 : 이미징 모달리티별

섹션 5 - 지역 시장 분석 및 예측

• 이 섹션의 내용
• 이 섹션을 읽는 이유
• 1. 북미 시장
• 2. 미국 시장
• 3. 캐나다 시장
• 4. 유럽 시장
• 5. 독일 시장
• 6. 프랑스 시장
• 7. 영국 시장
• 8. 이탈리아 시장
• 9. 스페인 시장
• 10. 기타 유럽 시장
• 11. 아시아태평양 시장
• 12. 중국 시장
• 13. 일본 시장
• 14. 인도 시장
• 15. 한국 시장
• 16. 호주 시장
• 17. 기타 아시아태평양 시장
• 18. 라틴아메리카 시장
• 19. 중동 및 아프리카 시장

도표 목록

표 목록

Volume 2 - 기업 개요

기업 개요 조사 방법

제1장 조사 방법의 개요

제2장 범위와 포함 로직

제3장 조사 입력

제4장 분석 워크플로우

제5장 프레임워크와 독자적인 도구

제6장 재무 모델링의 전제조건

제7장 품질 보증과 거버넌스

제8장 제한 사항

제9장 기업 개요 해석 방법

1. 4D Medical Ltd.

2. Accuray Inc.

3. Adiposs SA

4. Advanced Micro Devices(AMD)

5. Agfa HealthCare

6. Aidoc

7. AIQ Solutions

8. Airdoc

9. Annalise.ai

10. Align X-ray Insights

11. Artrya

12. Astute Imaging

13. Avicenna.ai

14. AZmed

15. Baidu

16. Bayer Radiology

17. BioMind

18. Blackford Analysis Ltd.

19. Bracco Imaging SpA

20. Brainlab AG

21. Brainomix Ltd.

22. BrightHeart.ai

23. Butterfly Network, Inc.(NYSE: BFLY)

24. CancerCenter.ai

25. Canon Medical Systems

26. Carestream

27. Caristo Diagnostics

28. CARPL.ai

29. CathWorks

30. Cellmatiq GmbH

31. Cerebra AI

32. Clarius Mobile Health

33. Cleerly

34. Combinostics Oy

35. ContextFlow GmbH

36. CoreTechs Labs

37. CureMetrix

38. deepc GmbH

39. DeepHealth(RadNet)

40. DeepMind(Google)

41. DeepSight Technology

42. DeepTek.ai

43. DEEPNOID INC

44. Deepwise

45. Diagnocat

46. Digital Diagnostics Inc

47. EchoNous

48. Elucid BioImaging

49. Enlitic

50. Envisionit Deep AI

51. Exo Inc

52. Ferrum Health

53. Fujifilm

54. GE Healthcare

55. Gleamer

56. Guerbet SA

57. Heartflow, Inc.

58. HeartFocus

59. Heuron

60. Hologic Inc

61. Huawei

62. Huiyihuiying(HY Medical)

63. Hyperfine

64. icometrix

65. ImageBiopsy

66. Imagen Technologies

67. Incepto Medical SAS

68. Infervision

69. JLK Inc

70. Koios Medical

71. Konica Minolta

72. LPIXEL

73. Lantheus Holdings

74. Lunit Inc.

75. Mediaire GmbH

76. Median Technologies

77. Medtronic PLC

78. Merative LP

79. Microsoft

80. Mindray Ltd

81. MSKai

82. Nanox Imaging Ltd.

83. Nico-Lab BV

84. NIRAMAI

85. NVIDIA

86. Olea Medical

87. Oracle

88. Oxipit

89. Perimeter Medical Imaging

90. Perspectum

91. Philips Healthcare

92. Pro Medicus, Ltd.

93. Qure.AI

94. Quibim

95. Radiobiotics

96. Rad AI

97. RapidAI

98. Samsung Healthcare

99. ScreenPoint Medical

100. Segami Corporation

101. Shenzhen Keya Medical Technology Co., Ltd

102. Shukun Technology/Careverse

103. Siemens Healthineers

104. Sirona Medical

105. Smart Soft Healthcare(CoLumbo)

106. Spectral AI

107. Stryker Corp

108. Subtle Medical

109. Synapsica

110. Tata Elxsi

111. Tempus AI

112. Tencent Holdings

113. Therapixel

114. Ultromics

115. United Imaging

116. Us2.ai

117. Vara AI

118. Vista AI

119. Viz.ai

120. VoxelCloud

121. VUNO

122. Zimmer Biomet

JHS

영문 목차

영문목차

Why This Study Matters

Radiology faces a triple squeeze: rising scan volumes, stagnant radiologist head count, and fast evolving reimbursement that now rewards computer assisted detection, triage, and quantification. AI is no longer experimental; it is operational. Capital allocation is shifting, yet market signals remain noisy-valuations, attach rate assumptions, and regulatory pace vary sharply by geography and modality. Marketstrat's "World Market for AI in Medical Imaging 2025-2032" cuts through that noise and offers a single, evidence weighted source of truth.

Market Snapshot

• Market size: US $2.7 B in 2023 -> US $28.4 B in 2032 (29.9 % CAGR).
• Growth catalysts: Enterprise "AI store" deals, NTAP & CADx CPT codes, Chinese subsidies, radiologist shortages.
• Modality mix: CT & MRI account for more than 60 % of spend today; Ultrasound accelerates after 2028.
• Clinical leaders: Oncology AI overtakes Neurology by 2028; Cardiology jumps to third as structured reporting matures.
• Regional dynamics: APAC growth rate surpasses Europe after 2027; North America remains the largest revenue pool through 2032.

Key Market Trends, Regional Growth, Strategic Implications for Vendors

The integration of artificial intelligence (AI) into the realm of medical imaging has shifted from an experimental curiosity to a mainstream imperative. This transition is driven by an intersection of factors:

• Global imaging procedure volumes continue to swell-estimates suggest that about 5 billion imaging exams (all modalities combined) are performed worldwide each year, with growth particularly prominent in emerging markets.
• Regulatory frameworks are increasingly accommodating: as of mid- to late-2023, the FDA has cleared or authorized nearly 700 AI/ML devices for healthcare applications, around 76% of which are in radiology (including diagnostic, triage, and workflow support tools).
• Clinical demand outpaces supply in many health systems, with radiologist shortages creating a ripe environment for AI-based workflow enhancements.

Within this ecosystem, Marketstrat sees AI solutions tackling a multi-faceted set of challenges-ranging from improved diagnostic accuracy and early detection of pathologies to greater efficiency in managing large volumes of scans. The market's double-digit CAGR forecasts reflect both genuine optimism about AI's potential and early but tangible clinical successes, particularly in oncology, neurology, and cardiovascular imaging.

Regional Growth Pattern

Accelerating but uneven

Marketstrat's analysis shows a near-30 % global CAGR, with the market growing from US $ 2.7 B in 2023 to US $ 28.4 B by 2032. Growth is led by:

• North America - largest absolute upside. Enterprise-size platform deals, value-based reimbursement for AI-assisted reads, and an accelerating replacement cycle to fully digital detector fleets underpin adoption.
• APAC - fastest expansion in dollar terms after North America, driven by China's multi-year AI subsidy program, Japan's new CADx reimbursement codes, and rapid rollouts in India/ASEAN private networks.
• Europe - steady uplift as MDR-certified algorithms are bundled into modality upgrades and national targets for cancer screening spur demand.
• LATAM & MEA - smaller bases but attractive pockets: conditional funding for TB/lung AI in Brazil and Saudi Arabia's Vision 2030 imaging buildouts lead the way.

Strategic Implications for Vendors

• 1. Platform over point-solutions - IDNs and public systems increasingly award multi-algorithm "AI store" contracts, favoring vendors with breadth and proven cybersecurity.
• 2. Local compliance is a moat - MDR in Europe and CFDA/GB standards in China create high-cost barriers that limit opportunistic entrants.
• 3. Emerging-market pricing power will erode - cloud-first SaaS bundles and OEM-embedded licensing models are becoming prerequisites for LATAM/MEA tenders.
• 4. Clinical-workflow integration is decisive - the largest deals hinge on seamless PACS/RIS integration, structured reporting, and audit trails for AI recommendations.

Bottom line: Capital availability, regulatory clarity, and enterprise IT readiness explain the regional growth deltas. Vendors that can align commercial models to these realities will capture disproportionate share as the market approaches the US $ 28.4 B mark by 2032.

Spotlight - Oncology Imaging AI Market

Oncology is the fastest professionalizing segment in AI driven medical imaging, growing from US $ 0.6 B in 2023 to an expected US $ 7.7 B by 2032 (32.7 % CAGR). Growth is propelled by three forces:

• 1. Clinical evidence: Large prospective trials in breast, lung and colon now show greater than or equal to 10 % sensitivity gain at constant specificity, catalyzing CPT and EU screening codes.
• 2. OEM platform pull: GE HealthCare, Siemens and Fuji embed multi tumor algorithms across CT, MR and RT consoles, tripling attach rates vs stand alone tools.
• 3. Capital light challengers: Cloud native pure plays from Korea, China and Israel deliver one tenth the on prem cost, expanding TAM in price sensitive regions.

North America retains >45 % of global profit through 2032 on the back of NTAP and Category I CPT momentum, while APAC overtakes Europe on volume by 2028 amid China's Class II lung screening mandate.

Strategic moves now: align product roadmaps with the CPT calendar (breast AI 2026, CT FFR lung 2026), publish greater than or equal to 10 peer reviewed real world studies, bundle oncology modules into enterprise AI suites, and tier SaaS pricing by GDP per capita to defend mature market ASPs while scaling emerging regions. Players executing on these levers are positioned to own the next inflection point in oncology imaging AI.

Why This Report

Marketstrat's "World Market for AI in Medical Imaging 2025-2032" goes several layers deep. Our dual lens methodology reconciles top down market sizing with bottom up attach rate and ASP calculations, all stress tested against licensed expert interview transcripts. Seven proprietary frameworks-M3, TEM, ARC, GTM Growth Maturity, Platform Leverage, Ecosystem Collaboration and Solution Adoption & Growth-translate raw data into decision tools that flag not just where the money is, but how fast it can be captured and at what risk.

The result is a single source of truth for OEM strategists, pure play AI vendors, investors and hospital procurement teams who need to quantify TAM, benchmark competitors and de risk capital allocation. If your growth plan depends on accurate attach rate assumptions, reimbursement scenarios or vendor evidence scoring, this is the report that turns market noise into actionable signal.

Seven proprietary strategy lenses-M3 Matrix, TEM Map, ARC Index, GTM Growth Maturity Quadrant, Platform Leverage Strip, Ecosystem Collaboration, and Solution Adoption & Growth Matrix-translate complex datasets into board ready visuals. Volume 1 delivers the macro picture and forecasts; Volume 2 profiles 120 vendors with side by side heat maps, attach rate models, and forward scenarios. Use the insights to benchmark competitors, stress test investment theses, or de risk purchasing decisions.

Report Stats

• Volume One: 380 page global market analysis with 160+ visuals and 155+Tables
• Volume Two: 515 page vendor compendium covering 120 companies and 600+ visuals
• Segmentation depth: Forecasts cut by five imaging modalities, seven clinical application areas, five geographic regions (twelve individual countries plus regional clusters), three revenue streams, five end-use or buyer segments / organizations, six AI technology categories.
• Time frame: 2023-24 actuals with 2025-2032 outlook - Market estimates and forecasts by segment
• Key proprietary analytical frameworks: M3 Matrix (size vs CAGR hotspots), TEM Map (technology maturity), ARC Index (approvals + reimbursement + clinical evidence), GTM Growth-Maturity Quadrant (vendor trajectory), Platform-Leverage Strip (ARR stickiness), Ecosystem Collaboration, and Solution Adoption & Growth Matrix (suite depth vs scaling velocity).
• Company Briefs: 120 Company profiles with frameworks & proprietary tools (Platform Leverage Strip, Growth & Maturity Heatmap, Attach-Rate Model, Reg-P Matrix). These briefs are decision tools. Numbers are directional, normalized for comparability, and best read alongside the underpinning sensitivity tables. Marketstrat Insights highlight levers-attach rate, modality expansion, and regulatory cadence. Use the Growth & Maturity Heatmap to gauge trajectory; deploy the Marketstrat Insight scenarios to stress test your own assumptions; consult the Watch Items to track each company's execution risk.
• Intended users: OEM and pure-play AI SW companies, investors sizing attach-rate upside, hospitals vetting vendor evidence before purchase, and regulators monitoring SaMD clearance velocity.

Table of Contents

Volume One - Market Analysis & Forecasts

SECTION 1 - EXECUTIVE SUMMARY

• Why This Market Matters - the 25-second Read
• Global Growth at a Glance
• Five Strategy Headlines to Internalize
• Where Growth Concentrates - Modality & Clinical Slices
• Regional Pulse - Inflection Points & Watchouts
• Competitive Heat the Five Moves to Track
• Three-year KPI Outlook (2024 -> 2027)
• Six Board-level Actions for the Next 12 Months
• Methodology Summary

SECTION 2 - RESEARCH METHODOLOGY

• About the Report
• Scope & Segmentation
• Marketstrat's "Insights -> Action" Approach
• Dual-Lens Architecture
• Top-Down Market Funnel
• Bottom up Attach Rate Flow
• Evidence Confidence - Density vs Reliability
• Framework Stack - Turning Insight into Action
• Quality Assurance Loop
• Limitations & Mitigations
• Company Briefs Methodology (Vol Two)

SECTION 3 - STRATEGIC MARKET ANALYSIS & FRAMEWORKS

• Why Read This Chapter?
• Outlook (2025-2030)
• Recommendations by Stakeholder Type
• Section Introduction
• Global Market & Procedure Volumes: Contextual Overview
  • Imaging Procedure Volumes
  • Core Reference - Annual Procedure Volumes
• Market Drivers and Restraints
  • Top Market Drivers (Ranked)
  • Top Market Restraints (Ranked)
• World Market Forecast by Region (2023-2032)
  • Regional Growth Pattern
  • Strategic Implications for Vendors
• Markintel M^3 Matrix (Market Momentum Matrix)
  • Portfolio Recommendations
  • Market Size vs. 2024-32 CAGR
  • Market Momentum by Modality
  • Market Momentum by Clinical Segment
  • Market Phases
  • Market Sensitivity - Tariffs & FX (2024-26)
• Markintel Technology Evolution Matrix (TEM)
  • TEM by Geographic Region
  • TEM by Imaging Modality
  • TEM by Clinical Application
  • Markintel TEM Scoring Framework - Methodology Snapshot
  • Markintel TEM by Region (2025) - Numeric Scorecard
• Markintel TDIT (Technology Diffusion and Impact Timeline)
  • TDIT Stage Definitions & Horizon
  • TDIT Quantitative Impact Tags
  • Key Inflection Drivers
  • Potential Roadblocks
  • Marketstrat Actionable Insights
• Markintel Solution Adoption & Growth Matrix - Worldwide
  • Immediate Strategic Recommendations
  • Quantification Guide
  • Illustrative Segment Scores
  • Quadrant Explanations & Global AI Solution Examples
• Marktintel ARC Index (Approvals, Reimbursement, Clinical Validation)
  • Markintel ARC Index by Use Case
    • Rationale for ARC Index Score by Use Case
  • Markintel ARC Index Score by Clinical Area
    • Oncology and Sub-Areas
    • Neurology and Sub-Areas
    • Cardiology and Sub-Areas
    • Respiratory/Pulmonary and Sub-Areas
    • Orthopedics and Sub-Areas
  • Regulatory and Compliance Trends
    • FDA Approvals: Key Details
    • Global Regulatory Landscape
    • Potential Shifts
    • FDA Clearances & Emerging Regulatory Landscapes
    • Regulatory & Reimbursement Snapshot - Update to Apr 2025
    • FDA Imaging-AI Clearances Heatmap, 2018 - 2025 YTD
    • Reimbursement Timeline Snapshot
    • FDA Clearances by Modality (cumulative Apr 2025)
    • Reimbursement Timeline Detail
• Markintel GTM Growth Maturity Matrix - World Market
• Competitive Dataset - World Market for AI Imaging
• Key Takeaways
• Growth & Maturity Highlights (selected)
• Competitive Landscape and Clusters
  • 1. Imaging OEM AI Suites
  • 2. AI-first Software Vendors
  • 3. Cloud & Platform Enablers
  • 4. Regional Champions
  • 5. Specialist Niches

SECTION 4 - WORLD MARKET ANALYSIS & FORECAST

• Section Overview
  • Why Read This Chapter?
  • Marketstrat Thesis
  • Regional Growth Picture
• World Market Forecast by Region (2023-2032, $ Mill)
  • Strategic Takeaways
  • Big-5 Regions CAGR Waterfall
• World Market Analysis by Clinical Area
  • Clinical Area Summary
    • Global Forecast by Clinical Area (2023-2032, USD Mill)
    • What the Numbers Mean for Strategists
    • Caveats & watch-points
    • Clinical Area Definitions
• Oncology Imaging AI Market Worldwide
  • Market Forecast by Region - Oncology Imaging AI (2023-2032, USD Mill)
  • Oncology Imaging AI: From Niche App to Enterprise Platform
  • Regional Growth Snapshot (2023 -> 2032)
  • Strategic Implications for Vendors
  • Market Momentum & Outlook
  • Markintel GTM Growth Maturity Framework - Oncology AI Worldwide
  • Competitive Dataset - Oncology AI Imaging
  • Competitive Context - Oncology AI
  • Strategic Takeaways - Oncology AI
  • Growth & Maturity Highlights (All Vendors)
  • Fast-Mover M&A Targets (Oncology AI)
  • Regulatory Velocity - New FDA Clearances Oncology Imaging AI
  • Modality-Reach Heatmap - Oncology Imaging AI 2024
  • Procedure Volumes
  • AI Applications & Adoption Trajectories
• Cardiology Imaging AI Market Worldwide
  • Market Forecast by Region (2023-2032, USD Mill)
  • Cardiology AI - Why Adoption is Breaking Out
  • Regional Growth Snapshot
  • Strategic Implications
  • Markintel GTM Growth Maturity Framework - Cardiology Imaging AI Worldwide
  • Competitive Dataset - Cardiology AI-Imaging
  • Competitive Context - Cardiology AI
  • Strategic Takeaways
  • Growth & Maturity Highlights - Cardiology Imaging AI
  • M&A Watch -- Fast-Moving Rising Stars
  • Regulatory Velocity - New Cardiology AI Imaging Clearances (Mar 2024 to June 2025)
  • Modality-Reach Heatmap - Cardiology AI 2024
  • Procedure Volumes
  • AI Applications & Adoption
  • Future Directions
• Neurology Imaging AI Market Worldwide
  • Market Forecast by Region (2023-2032, USD Mill)
  • Why Adoption is Moving Beyond Stroke Triage
  • Regional Growth Snapshot
  • Strategic Implications
  • Markintel GTM Growth Maturity Framework - Neurology Imaging AI Worldwide
  • Competitive Dataset - Neurology AI-Imaging
  • Competitive Context - Neurology AI
  • Strategic Takeaways
  • Growth and Maturity Highlights - Neurology AI Imaging
  • Fast-Mover M&A Watch-List - Neurology AI
  • Regulatory Velocity - New Neuro-AI Clearances - Neurology AI Imaging (Mar '24 - Jun '25)
  • Modality Reach Heat-Map - Neurology AI 2024
  • Procedure Volumes - Neurology Imaging AI
  • AI Use-Cases
  • Market Evolution
• Respiratory Imaging AI Market Worldwide
  • Market Forecasts by Region (2023 - 2032, USD Mill)
  • What Ignited the 2024 Breakout
  • Regional Growth Snapshot
  • Strategic Implications
  • Markintel GTM Growth Maturity Framework - Respiratory Imaging AI - World
  • Competitive Dataset - Respiratory AI Imaging
  • Competitive Context - Respiratory AI
  • Strategic Takeaways
  • Growth and Maturity Highlights
  • Fast-Mover M&A Watchlist
  • Regulatory Velocity - New Respiratory-AI Clearances (Mar '24 - Jun '25)
  • Modality Reach Heat-Map - Respiratory Imaging AI Worldwide - 2024
• Orthopedic/MSK Imaging AI Market Worldwide
  • Market Forecasts by Region (2023 - 2032, USD Mill)
  • What is Driving Acceleration
  • Regional Growth Snapshot
  • Strategic Implications
  • Markintel GTM Growth Maturity Framework - Orthopedic/MSK Imaging AI - World
  • Competitive Dataset - Orthopedic Imaging AI
  • Competitive Context - MSK (Orthopedic) AI
  • Strategic Takeaways
  • Growth and Maturity Highlights
  • Fast-Mover M&A Watchlist
  • Procedure Volumes
  • AI Adoption & Key Applications
  • Regulatory Velocity - Orthopedic (MSK) Imaging AI Worldwide - (Mar '24 - Jun '25)
  • Use Cases
  • AI Solutions
  • Modality Reach Heat-Map - Orthopedic (MSK) AI
• Other Clinical Areas Imaging AI Market Worldwide
  • Market Forecasts by Region (2023 - 2032, USD Mill)
  • Segment Overview & Characteristics
  • Regional Snapshot
  • Strategic Takeaways
  • Revenue Breakdown - "Other" Clinical Areas Worldwide (2024)
  • Sub-Areas, Use Cases, Vendors
  • Reimbursement Readiness Heatmap
  • Depth vs Breadth Snapshot
  • Regulatory Velocity - Other Clinical Areas Imaging AI (Mar '24 - Jun '25)
  • Strategic Takeaways
  • M&A Watchlist
• World Market Analysis by Imaging Modality
  • Modality Outlook: Where AI Value Pools Shift Through 2032
    • Highlights
    • Global Forecast by Modality (2023-2032, USD Mill)
    • Market Math & Diffusion Pattern
    • Strategic Takeaways for Vendors
    • Modality Definitions
  • CT Modality Imaging AI Market Worldwide
    • Market Forecast by Region - CT Imaging AI (2023 - 2032, USD Mill)
    • Regional mix in 2032
    • Adoption Accelerators
    • Strategic implications for vendors
    • Markintel GTM Growth and Maturity Matrix - CT Imaging AI - World
    • Competitive Dataset - CT AI-Imaging
    • Growth and Maturity Highlights - CT AI-Imaging Companies
    • Competitive Context - CT modality AI
    • Strategic Takeaways for 2024-2027
    • M&A Watchlist - Global CT AI
    • Regulatory Velocity - CT-Specific Clearances
    • Attach-Rate by Region (CT only, 2024)
    • Revenue Split (Factory vs Retrofit) by Region - CT
    • Procedure Volumes & Applications
  • MRI Modality Imaging AI Market Worldwide
    • Market Forecast by Region - MRI Imaging AI (2023 - 2032, USD Mill)
    • Regional Mix in 2032
    • Adoption Accelerators
    • Strategic Implications
    • Markintel GTM Growth and Maturity Matrix - MRI Imaging AI - World
    • Competitive Dataset - MRI AI-Imaging
    • Growth and Maturity Highlights - MRI AI-Imaging Companies
    • Competitive Context - MRI AI Modality
    • Strategic Takeaways for 2024 - 2027
    • M&A Watchlist - Global MRI AI
    • Regulatory Velocity (MRI-AI Clearances)
    • Attach-Rate by Region - MRI
    • Factory vs Retrofit Revenue Split (MRI, 2024)
    • Procedure Volumes & Applications
  • X-ray Modality Imaging AI Market Worldwide
    • Market Forecast by Region - X-ray Imaging AI (2023-2032, USD Mill)
    • Regional Split - 2032
    • Adoption Accelerators
    • Strategic implications
    • Markintel GTM Growth and Maturity Matrix - X-ray Imaging AI - World
    • Competitive Dataset
    • Growth and Maturity Highlights - X-ray AI-Imaging Companies
    • Competitive Context - X-ray Modality AI
    • Strategic Takeaways 2024-27
    • M&A Watchlist - Global X-ray-AI
    • Regulatory Velocity - X-ray AI
    • Attach-Rate by Region (X-ray, 2024)
    • Factory vs Retrofit Revenue Split (X-ray, 2024)
    • Market & Procedure Volumes
  • Ultrasound Modality Imaging AI Market Worldwide
    • Market Forecast by Region - Ultrasound Imaging AI (2023-2032, USD Mill)
    • Regional Split - 2032
    • Adoption Accelerators
    • Strategic Market Implications
    • Markintel GTM Growth and Maturity Matrix - Ultrasound AI - World
    • Competitive Dataset - FY-2024 Ultrasound AI-Imaging (Worldwide)
    • Growth & Maturity Highlights - Ultrasound AI
    • Competitive Context - Ultrasound AI
    • Strategic Takeaways 2024-2027
    • AI M&A Watchlist - Global Ultrasound
    • Regulatory Velocity - Ultrasound AI (Mar-23 -> Mar-24)
    • Attach-Rate by Region (Ultrasound)
    • Factory vs Retrofit Revenue Split (Ultrasound)
    • Market & Procedure Volumes
  • Nuclear/PET Modality Imaging AI Market Worldwide
    • Market Forecast by Region (2023-2032, USD Mill)
    • Regional Split - 2032
    • Adoption Accelerators
    • Strategic Market Implications
    • Markintel GTM Growth and Maturity Matrix - Nuclear/PET imaging AI - World
    • Competitive Dataset - Nuclear/PET AI-Imaging
    • Growth & Maturity Highlights - Nuclear / PET AI
    • Competitive Context - Nuclear/PET AI
    • Strategic Takeaways
    • M&A Watchlist - Nuclear/PET Imaging
    • Market & Procedure Volumes
  • World Market Analysis by Revenue Stream
    • Forecast by Revenue Stream (2023-2032, USD Mill)
    • Revenue-Stream Dynamics
    • Regional Color
    • Strategic Takeaways
    • Revenue Stream Segments
• World Market Analysis by Clinical Application
  • Forecast by Clinical Application (2023-2032, USD Mill)
  • Functional Value Pools
  • Regional Color
  • Strategic Takeaways
  • Use-Case/Workflow Segmentation
  • AI Clinical Solutions
• World Market Analysis by End-Use Organization
  • Forecast by End-Use Organization (2023-2032, $US Mill)
  • Buyer Mix Shift
  • Regional Color
  • Strategic Implications
  • End-Use Org Definitions
• World Market Analysis by AI Technology
  • Forecast by AI Technology (2023-2032, $US Mill)
  • Technology Mix
  • Regional Color
  • Strategic Takeaways
  • AI Technology Definitions and Applications
    • Deep Learning
    • Computer Vision (Classical)
    • Machine Learning (Traditional)
    • Natural Language Processing (NLP)
    • Robotics
    • Expert Systems
  • Summary Comparison of AI Technologies
  • Key Takeaways

SECTION 5 - REGIONAL MARKET ANALYSIS & FORECAST

• What's in This Section?
• Why Read This Section?
• 1. NORTH AMERICAN MARKET
  • Market Summary
    • Market Size & Drivers
    • Latest Trends
    • Strategic Outlook
    • Competitive Environment
    • New Focus Areas
  • North American Market Estimates & Forecasts (2023-2032)
  • AI Imaging Market by Country - North America
    • What's Driving the Numbers
    • Implications
  • Markintel GTM Growth and Maturity Matrix - North America
  • Competitive Dataset - North America
  • Competitive Context - North America AI-Imaging 2024
  • Strategic Takeaways
  • Growth & Maturity Highlights - North America
  • M&A Watchlist - North America Rising Stars
  • Regulatory Velocity - North America
• Source: Marketstrat Analysis of Public Data
  • OEM AI Attach-Rate by Modality
• Source: Marketstrat Analysis
  • Attach Rate Trends - North America
  • Factory vs Retrofit - North America
• 2. UNITED STATES MARKET
  • Market Summary - United States
    • Key Market Dynamics
    • Strategic Takeaways
    • Top 3 Recommendations
  • Market Overview - United States
    • Demographics & Epidemiology
    • Macro economics & Health Spending
    • Imaging Volume & Installed Base
    • Regulatory & Reimbursement Snapshot
    • Healthcare Delivery & Practice Patterns
    • AI Market Dynamics (Imaging)
    • Competitive Landscape
    • Takeaways for Vendors
  • US Market by Clinical Area
    • Forecast by Clinical Area (2023-2032, USD Mill)
    • U.S. AI-Imaging Outlook by Clinical Area (2023 -> 2032)
    • Key Dynamics to Watch
    • Implications for Vendors
    • US Market by Imaging Modality
    • Forecast by Modality (2023-2032, USD Mill)
    • U.S. Modality Outlook: Who Grows, Who Overtakes
    • Key Takeaways
  • US Market by Revenue Stream
    • Forecast by Revenue Stream (2023-2032, USD Mill)
    • U.S. Revenue Stream Shift: From Capital Boxes to Recurring Bytes
    • What's Driving the Mix Change
    • Implications for Vendors
  • US Market by Clinical Application
    • Forecast by Clinical Application (2023-2032, USD Mill)
    • Outlook by Clinical Application
    • Highlights
    • Implications
  • US Market by End-Use Organization
    • Forecast by End-Use Organization (2023-2032, USD Mill)
    • Who Buys AI-and How That Mix Shifts Through 2032
    • What's Behind the Shift
    • Strategic Implications for Vendors
  • US Market by AI Technology
    • Forecast by AI Technology (2023-2032, USD Mill)
    • Outlook by Core Technology (2023-2032)
• Markintel Growth Maturity Matrix - US & Canada
  • Competitive Dataset - United States
  • Competitive Context - U.S./North America
  • What to Watch Next
• Markintel Solution Adoption & Growth Matrix - US & Canada
  • Scorecard - Solution Adoption & Growth Matrix (U.S. & Canada)
  • Strategic Implications for Stakeholders
• Markintel Ecosystem Collaboration Matrix - US & Canada
  • Who to Partner with and How Deep?
  • What Succeess Looks Like in Each Quadrant
  • Stratregic Guidance
• GTM at a Glance - United States
  • Channel & Pricing Matrix
  • GTM Readiness Radar - US
  • Customer Tier Potential - US
  • GTM Timeline (2025-2028) - US
  • Fast Strategic Cues (2025)
  • Regulatory x Funding Heatmap - US
  • Adjacency-Opportunity Radar - US
  • Whitespace Partner-Fit Matrix - US
• 3. CANADIAN MARKET
  • Market Summary: Canada
    • Key Market Dynamics
    • Strategic Takeaways
    • Top 3 Recommendations
  • Market Overview - Canada
    • Demographics & Epidemiology
    • Imaging Supply & Utilization
    • Health System & Practice Patterns
    • Regulatory & Reimbursement
    • AI-Imaging Market Dynamics
    • Competitive Snapshot
    • Key Implications
  • Canadian Market by Clinical Area
    • Forecast by Clinical Area (2023-2032, USD Mill)
    • Outlook by Clinical Area
    • Key Dynamics to Watch
    • Implications for Vendors
  • Canadian Market by Imaging Modality
    • Forecast by Imaging Modality (2023-2032, USD Mill)
    • Outlook by Modality
    • Key Dynamics to Watch (2025-27)
    • Implications for Vendors
  • Canadian Market by Revenue Stream
    • Forecast by Revenue Stream (2023-2032, USD Mill)
    • What's Driving Each Revenue Stream
    • Key Dynamics to Watch
    • Implications for Vendors
  • Canadian Market by Clinical Application
    • Forecast by Clinical Application (2023-2032, USD Mill)
    • Outlook & Drivers by Application
    • Key Market Dynamics to 2027
    • Implications for Vendors and Providers
  • Canadian Market by End-Use Organization
    • Forecast by End-Use Organization (2023-2032, USD Mill)
    • Outlook 2025-2032
    • Key Drivers by Segment
    • Implications for Vendors
    • Strategic Takeaways
  • Canadian Market by AI Technology
    • Forecast by AI Technology (2023-2032, USD Mill)
    • Highlights by Technology
    • Key Dynamics to Watch (2025 27)
    • Implications for Vendors & Providers
  • GTM at a Glance - Canada
    • GTM Readiness Radar - Canada
    • Tiered Customer Landscape
    • Channel & Pricing Matrix
    • GTM Timeline (Canada)
    • Fast Cues for 2025 Stakeholders
• 4. EUROPEAN MARKET
  • Market Overview & Analysis
    • Market Snapshot
    • Structural Demand Signals
    • Regulatory & Funding Landscape (2024-2028)
    • Market Segmentation 2032 (value share)
    • Competitive Heat Map (2024-26)
    • Execution Playbook (2024-2027)
    • Action-Oriented Recommendations
  • European Market Estimates and Forecasts by Country (2023-2032, USD Mill)
    • Five Forces Shaping Adoption
    • Country Archetypes & What Sells
    • Near term Adoption Runway (2024-27)
    • Strategic Implications
  • Regulatory Velocity by Company - Europe
  • Markintel Growth Maturity Matrix - Europe
    • Landscape Snapshot
    • Why the Quadrant Looks the Way it Does
    • Key Competitive Dynamics
    • Strategic Takeaways
    • Bottom Line
    • M&A Watchlist - Europe
    • Competitive Dataset - Europe
    • Growth & Maturity Highlights - Europe
  • Markintel Ecosystem Collaboration Matrix (ECM) - Europe
    • Quadrant Commentary & European Illustrations
    • Action Checklist
  • Markintel Solution Adoption & Growth Matrix - Europe
    • Quadrant Deep Dive
    • What Moves a Solution from One Box to the Next?
    • Strategic Guidance
  • AI Attach Rate - Europe
    • OEM AI Attach Rate
    • Attach Rate Trends - Europe
    • AI Revenue Split - Factory vs Retrofit Attach -- Europe
  • GTM at a Glance - Europe
    • Channel & Pricing Matrix (2025-2028)
    • GTM Readiness Radar - Europe
    • Tiered Customer Landscape (2032 View)
    • GTM Timeline (2025 -> 2028) - Europe
    • Adjacency Opportunity Radar (2026+) - Europe
    • Regulatory x Funding Heatmap - Europe
    • AI Imaging Whitespace Matrix - Europe
    • Fast Strategic Cues (2025 playbook)
• 5. GERMAN MARKET
  • Market Overview - Germany
    • Macro & Epidemiology
    • Health system & Funding Landscape
    • Regulatory & Evidence Pathway
    • Competitive Landscape
    • Strategic Takeaways & Recommendations
  • German Market by Clinical Area
    • Forecast by Clinical Area (2023-2032, USD Mill)
    • Primary Growth Catalysts
    • Strategic Messages for Stakeholders
    • Key Takeaways
  • German Market by Modality (2023-2032, USD Million)
    • Forecast by Modality (2023-2032, USD Mill)
    • Key Inflection by Modality
    • What's Driving Each Modality
    • Strategic Implications
  • German Market by Revenue Stream (2023-2032, USD Million)
    • Forecast by Revenue Stream (2023-2032, USD Mill)
    • Revenue Streams and Drivers
    • Key Dynamics by Stream
    • Strategic Guidance
  • German Market by Clinical Application (2023-2032, USD Million)
    • Forecast by Clinical Application (2023-2032, USD Mill)
    • What is Driving Each Bucket
    • Strategic Messages
    • Action Playbook
  • German Market by End-Use Organization (2023-2032, USD Million)
    • Forecast by End-Use Organization (2023-2032, USD Mill)
    • Segments Review
    • Strategic Implications
  • German Market by AI Technology (2023-2032, USD Million)
    • Forecast by AI Technology (2023-2032, USD Mill)
    • Germany - AI Imaging Market by Core Technology
    • Why Deep Learning Keeps the Lion's Share
    • Break-out Growth Themes
    • Strategic Playbook
  • GTM at-a-Glance
    • Channel x Pricing Matrix
    • GTM Readiness Radar - Germany
    • Tiered Customer Landscape
    • GTM Timeline - Germany
    • Fast Strategic Cues
• 6. FRENCH MARKET
  • Market Summary: France
    • Top line Snapshot - France
    • Key Market Dynamics
    • Strategic Takeaways
    • Top 3 Recommendations
    • French Market Speed scan - Market Analysis (2024 2032)
  • French Market Estimates and Forecasts (2023-2032)
    • French Market by Clinical Area (2023-2032)
    • French Market by Modality (2023-2032)
    • French Market by Revenue Stream (2023-2032)
    • French Market by Clinical Application (2023-2032)
    • French Market by End-Use Organization (2023-2032)
    • French Market by AI Technology (2023-2032)
    • Quick Strategic Cues - France GTM
  • GTM at a Glance - France
    • Channel x Pricing Matrix
    • GTM Readiness Radar - What Counts Most in France
    • GTM Timeline (2024 30) - France
    • Spend Potential by Customer Tier - France
• 7. UNITED KINGDOM MARKET
  • Market Overview - United Kingdom
  • UK Market Speed Scan
  • UK Market Estimates and Forecasts (2023-2032)
    • UK Market by Clinical Area (2023-2032)
    • UK Market by Modality (2023-2032)
    • UK Market by Revenue Stream (2023-2032)
    • UK Market by Clinical Application (2023-2032)
    • UK Market by End-Use Organization (2023-2032)
    • UK Market by AI Technology (2023-2032)
  • GTM at a Glance - UK
    • Channel x Pricing Matrix
    • GTM Readiness Radar - UK
    • Fast Strategic Cues
    • Tiered Customer Landscape
    • GTM Timeline (2024 29) - UK
• 8. ITALIAN MARKET
  • Market Overview & Summary: Italy
    • What Makes Italy Unique in the EU Context
    • Strategic Takeaways
  • Italian Market Estimates & Forecasts (2023-2032)
    • Italian Market by Clinical Area (2023-2032)
    • Italian by Modality (2023-2032)
    • Italian Market by Revenue Stream (2023-2032)
    • Italian Market by Clinical Application (2023-2032)
    • Italian Market by End-Use Organization (2023-2032)
    • Italian Market by AI Technology (2023-2032)
  • GTM at a Glance - Italy
    • 1. Channel x Pricing Matrix
    • 2. Tiered Customer Landscape & Spend Potential (2032)
    • 3. GTM Readiness Radar - Italy
    • 4. GTM Timeline (2024-29) - Italy
    • 5. Fast Strategic Cues
• 9. SPANISH MARKET
  • Market Overview & Summary - Spain
  • Strategic Takeaways
  • Spanish Market Estimates and Forecasts (2023-2032)
    • Spanish Market by Clinical Area (2023-2032)
    • Spanish Market by Modality (2023-2032)
    • Spanish Market by Clinical Application (2023-2032)
    • Spanish Market by Revenue Stream (2023-2032)
    • Spanish Market by End-Use Organization (2023-2032)
    • Spanish Market by AI Technology (2023-2032)
  • GTM at a Glance - Spain
    • GTM Readiness Radar - Spain
    • Channel x Pricing Matrix
    • Tiered Customer Landscape - Spain
    • GTM Timeline - Spain
• 10. REST OF EUROPE (ROE) MARKET
  • Market Overview: Rest of Europe (ROE)
  • Strategic Takeaways
  • Rest of European Market for AI in Medical Imaging (2023-2032)
    • Rest of European Market by Clinical Area (2023-2032)
    • Rest of European Market by Modality (2023-2032)
    • Rest of European Market by Revenue Stream (2023-2032)
    • Rest of European Market by Clinical Application (2023-2032)
    • Rest of European Market by End-Use Organization (2023-2032)
    • Rest of European Market by AI Technology (2023-2032)
  • GTM at a Glance - Rest of Europe (ROE)
    • GTM Readiness Radar - ROE
    • Tiered Customer Landscape - ROE
    • GTM Timeline - ROE
    • Channel x Pricing Matrix
    • Adjacency-Opportunity Matrix (2026-2030)
    • Country-Cluster Framework & Strategic Playbook
    • White-Space Partnership Matrix
    • Regulatory Funding Heatmap (ROE Clusters)
    • Fast Strategic Cues
• 11. ASIA-PACIFIC (APAC) MARKET
  • Size, Trajectory & Strategic Importance
  • Demand Drivers & Headwinds
  • Competitive & Partnership Landscape
  • Strategic Clustering & Go-to-Market Nuances
  • Strategic Recommendations
  • AI Imaging Market by Country - APAC
  • Markintel GTM Growth and Maturity Matrix - APAC
    • Competitive Data Set - APAC
    • Numbers-in-Context - APAC
    • Strategic Takeaways - APAC
    • Growth & Maturity Highlights - APAC
    • M&A Watchlist - APAC
  • Regulatory Velocity - APAC
  • OEM AI Attach Rate - APAC
  • Attach-Rate Trends - APAC
  • GTM at a Glance - APAC
    • GTM Readiness Radar - APAC
    • Tiered Customer Landscape - APAC
    • GTM Timeline - APAC
    • Adjacency Opportunity Matrix - APAC
    • Country-Cluster Framework - APAC
    • White Space Partner Framework - APAC
    • Regulatory Funding Heatmap - APAC
    • Channel x Pricing Matrix - APAC
    • Fast Strategic Cues - APAC
• 12. CHINESE MARKET
  • China - Market Overview & Strategic Summary (2023-2032)
    • Strategic Takeaways
  • Chinese Market Forecasts (2023-2032)
    • Chinese Market by Clinical Area (2023-2032)
    • Chinese Market by Modality (2023-2032)
    • Chinese Market by Revenue Stream (2023-2032)
    • Chinese Market by Clinical Application (2023-2032)
    • Chinese Market by End-Use Organization (2023-2032)
    • Chinese Market by AI Technology (2023-2032)
  • Markintel Growth Maturity Matrix - China AI in Medical Imaging
    • Executive Commentary
    • Cross-Quadrant Insights & Tactical Guidance
    • Priority Recommendations (next 18 months)
    • Competitive Dataset - China
  • Markintel Ecosystem Collaboration Matrix - China
    • Decoding the 2 x 2 and Turning it into Action
    • Three Rules for Winning the Collaboration Game
    • Quick hit Actions for BD teams (Next Two Quarters)
  • Markintel Solution Adoption and Growth Matrix - China
    • Translating the Matrix into Action
    • Execution Priorities by Function
    • "First 100-Days" Checklist
    • Metrics that Matter
    • Operating Roadmap Takeaway
  • GTM at a Glance - China
    • GTM Readiness Radar - China
    • Tiered Customer Landscape - China
    • GTM Timeline - China
    • Adjacency-Opportunity Radar - China
    • Regulatory Funding Heatmap - China
    • Channel x Pricing Matrix - China
    • White Space Partnership Matrix - China
• 13. JAPANESE MARKET
  • Market Overview & Strategic Summary: Japan
    • Strategic Outlook
    • Action Points
  • Japanese Market Forecasts (2023-2032)
    • Japanese Market by Clinical Area (2023-2032)
    • Japanese Market by Modality (2023-2032)
    • Japanese Market by Revenue Stream (2023-2032)
    • Japanese Market by Clinical Application (2023-2032)
    • Japanese Market by End-Use Organization (2023-2032)
    • Japanese Market by AI Technology (2023-2032)
  • Markintel Solution Adoption & Growth Matrix - Japan
    • Turning the Matrix into an Operating Road Map for Japan (2024 28)
  • Markintel Ecosystem Collaboration Matrix - Japan
    • Turning the Matrix into an Operating Roadmap
    • Playbook Highlights by Quadrant
    • Risk Checkpoints & Mitigations
  • Go-to-Market (GTM) Playbook - Japan
    • GTM Readiness Radar - Japan
    • Tiered Customer Landscape - Japan
    • GTM Timeline - Japan
    • Adjacency Opportunity Radar - Japan
    • Regulatory Funding Heatmap - Japan
    • Channel x Pricing Matrix - Japan
    • White Space Partnership Matrix - Japan
    • Fast Strategic Cues
• 14. INDIAN MARKET
  • Market Overview & Analysis
    • Executive Snapshot
    • Market Mechanics
    • Constraint Map
    • Competitive Temperature ("5 P" quick lens)
    • Actionable Opportunities (2024-26 Window)
    • Go Forward Recommendations (by player type)
    • What Success Looks Like
  • Indian Market Forecasts (2023-2032)
    • Indian Market by Clinical Area (2023-2032)
    • Indian Market by Modality (2023-2032)
    • Indian Market by Revenue Stream (2023-2032)
    • Indian Market by Clinical Application (2023-2032)
    • Indian Market by End-Use Organization (2023-2032)
    • Indian Market by AI Technology (2023-2032)
  • Markintel Solution Adoption & Growth Matrix - India
    • Solution Classes and Action Cues
    • Strategic Interpretation & Operating Roadmap
    • One-Page Operating Checklist
  • Markintel Ecosystem Collaboration Matrix - India
    • Operating Roadmap: Leveraging India's Collaboration Matrix
    • Strategic Sequencing (2024 27)
    • Execution Tips
    • Key Metrics to Track
  • Competitive Landscape - India
    • Key Competitive Insights
    • Operating Roadmap
  • GTM at a Glance - India
    • GTM Readiness Radar - India
    • Tiered Customer Landscape - India
    • GTM Timeline - India
    • Adjacency-Opportunity Radar - India
    • Regulatory x Funding Heatmap - India
    • White-Space Partnership Matrix
    • Channel x Pricing Matrix
    • Fast Strategic Cues (Do This First)
• 15. SOUTH KOREAN MARKET
  • Market Summary: South Korea
    • Key Market Dynamics
    • Strategic Takeaways
    • Top 3 Recommendations
  • South Korean Market Forecasts (2023-2032)
    • South Korean Market by Clinical Area (2023-2032)
    • South Korean Market by Modality (2023-2032)
    • South Korean Market by Revenue Stream (2023-2032)
    • South Korean Market by Clinical Application (2023-2032)
    • South Korean Market by End-Use Organization Type (2023-2032)
    • South Korean Market by AI Technology (2023-2032)
  • GTM at a Glance - South Korea
    • Six-Pillar GTM Readiness Radar - South Korea
    • Tiered Customer Landscape - South Korea
    • Five-Step GTM Timeline - South Korea
    • Adjacency-Opportunity Radar - South Korea
    • Regulatory x Funding Heatmap - South Korea
    • Whitespace Partnership Matrix - South Korea
    • Channel x Pricing Matrix - Typical 2025 Deals
    • Fast Strategic Cues
• 16. AUSTRALIAN MARKET
  • Market Overview & Analysis
    • Market Structure & Growth Drivers
    • Segment Hotspots (Qualitative Sizing)
    • Competitive Landscape
    • Strategic Implications & GTM Priorities
    • Action-Oriented Recommendations (Next 12 Months)
  • Australian Market Forecasts (2023-2032)
    • Australian Market by Clinical Area (2023-2032)
    • Australian Market by Modality (2023-2032)
    • Australian Market by Revenue Stream (2023-2032)
    • Australian Market by Clinical Application (2023-2032)
    • Australian Market by End-Use Organization (2023-2032)
    • Australian Market by AI Technology (2023-2032)
  • GTM at a Glance - Australia
    • GTM Readiness Radar - Australia
    • GTM Timeline - Australia
    • Adjacency-Opportunity Radar - Australia
    • Regulatory x Funding Heatmap
• 17. REST OF ASIA-PACIFIC (ROAPAC) MARKET
  • Market Overview & Analysis
    • Regional Clusters
    • Market Dynamics - What's Shaping Buying Decisions
    • Actionable Recommendations
    • Quick-Hit Opportunities by Cluster
    • What Success Looks Like
  • Rest of Asia-Pacific Market Forecasts (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Clinical Area (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Modality (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Revenue Stream (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Clinical Application (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by End-Use Organization (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by AI Technology (2023-2032)
  • GTM at a Glance - ROAPAC
    • GTM Readiness Heatmap - ROAPAC Clusters
    • Five-Step GTM Roll Out Timeline (2024 2029) - Keyed to Clusters
• 18. LATIN AMERICAN (LATAM) MARKET
  • Market Overview & Analysis: Latin America (LATAM)
    • Market Summary
    • Growth Driver Waterfall - LATAM
    • Geo Economic Clusters (for GTM focus)
    • Segment Trends to 2032
    • Regulatory Snapshot (big 5)
    • Action-Oriented Recommendations
  • LATAM Market Estimates and Forecasts
    • LATAM Market by Clinical Area (2023-2032)
    • LATAM Market by Modality (2023-2032)
    • LATAM Market by Revenue Stream (2023-2032)
    • LATAM Market by Clinical Application (2023-2032)
    • LATAM Market by End-Use Organization (2023-2032)
    • LATAM Market by AI Technology (2023-2032)
  • Markintel Solution Adoption & Growth Matrix - LATAM
    • Cross Quadrant Operating Roadmap (2024 27)
  • Markintel Ecosystem Collaboration Matrix - LATAM
    • Operating Roadmap (90 Day Focus)
  • GTM at-a-Glance - LATAM
    • GTM Readiness Radar - LATAM
    • GTM Timeline - LATAM
    • LATAM Country Clusters Summary
    • Cluster-Priority Heatmap
    • Regulatory Velocity & Reimbursement Pulse - LATAM
    • OEM AI Attach Rate - LATAM
    • GTM Maturity Highlights by Company - LATAM
• 19. MIDDLE EAST & AFRICAN MARKET
  • Market Overview & Analysis: Middle East & Africa (MEA)
    • LATAM Snapshot
    • Logical Clusters & Why They Matter
    • Key Growth Catalysts
    • Structural Barriers & Mitigation
    • Actionable Recommendations by Vendor Type
    • Sequencing Roadmap
    • Executive Takeaways
  • Middle East & Africa (MEA) - Market Estimates and Forecasts
    • MEA Market by Clinical Area (2023-2032)
    • MEA Market by Modality (2023-2032)
    • MEA Market by Revenue Stream (2023-2032)
    • MEA Market by Clinical Application (2023-2032)
    • MEA Market by End-Use Organization (2023-2032)
    • MEA Market by AI Technology (2023-2032)
  • Markintel Solution Adoption & Growth Matrix - MEA
    • Interpretation & Operating Roadmap
    • Execution Checklist
  • Markintel Ecosystem Collaboration Matrix - MEA
    • Partnership Playbook
    • Operating Roadmap & Key Execution Metrics
  • GTM at-a-Glance - Middle East & Africa (MEA)
    • GTM Readiness Radar - MEA
    • Country Cluster Heatmap - MEA
    • GTM Timeline - Pilot to Scale (2024-2029) - MEA
    • Adjacency-Opportunity Radar - MEA
    • GTM Maturity Highlights
    • Regulatory Velocity - MEA
    • Attach Rate Trends - MEA

List of Figures

• Figure 1: Global AI-Imaging Revenue (2023-2032)
• Figure 2: Market Momentum Matrix (M3) by Modality Worldwide
• Figure 3: Top-Down Market Funnel
• Figure 4: Bottom-up Attach Rate Flow (CT/MRI Example)
• Figure 5: Evidence Confidence - Density vs Reliability
• Figure 6: Annual Imaging Procedure Volumes by Modality
• Figure 7: Market Drivers and Restraints
• Figure 8: Markintel M^3 Matrix (Market Momentum Matrix) Global
• Figure 9: Market Momentum by Modality (Global)
• Figure 10: Markintel Technology Evolution Matrix (TEM) by Region
• Figure 11: Markintel Technology Evolution Matrix (TEM) by Imaging Modality
• Figure 12: Markintel Technology Evolution Matrix (TEM) by Clinical Application
• Figure 13: Markintel TDIT (Technology Diffusion and Impact Timeline)
• Figure 14: Markintel Solution Adoption & Growth Matrix - Worldwide
• Figure 15: Marktintel ARC Index (Approvals, Reimbursement, Clinical Validation) by Use Case
• Figure 16: Marktintel ARC Index Score - Oncology & Sub-Areas
• Figure 17: Marktintel ARC Index Score - Neurology & Sub-Areas
• Figure 18: Marktintel ARC Index Score - Cardiology & Sub-Areas
• Figure 19: Marktintel ARC Index Score - Resp/Pulmonary & Sub-Areas
• Figure 20: Marktintel ARC Index Score - Orthopedics & Sub-Areas
• Figure 21: FDA Imaging-AI Clearances Heatmap, 2018 - 2025 YTD
• Figure 22: Reimbursement Timeline Snapshot by Region & Clinical Area (2020-2027)
• Figure 23: Markintel GTM Growth Maturity Matrix - World Market
• Figure 24: World Market for AI in Medical Imaging by Geographic Region (2023-2032, USD Million)
• Figure 25: Big-5 Geographic Regions CAGR Waterfall
• Figure 26: Markintel GTM Growth vs Maturity - Oncology Imaging AI Worldwide
• Figure 27: Oncology Imaging AI FDA Clearances by Qtr
• Figure 28: Modality-Reach Heatmap - Oncology Imaging AI 2024
• Figure 29: Markintel GTM Growth Maturity Framework - Cardiology Imaging AI Worldwide
• Figure 30: Regulatory Velocity - New Cardiology AI Imaging Clearances (Mar 2024 to June 2025)
• Figure 31: Modality-Reach Heatmap - Cardiology AI 2024
• Figure 32: Markintel GTM Growth Maturity Framework - Neurology Imaging AI Worldwide
• Figure 33: Regulatory Velocity - New Neuro-AI Clearances - Neurology AI Imaging (Mar '24 - Jun '25)
• Figure 34: Modality Reach Heat-Map - Neurology AI 2024
• Figure 35: Markintel GTM Growth Maturity Framework - Respiratory Imaging AI - World
• Figure 36: Regulatory Velocity - New Respiratory-AI Clearances (Mar '24 - Jun '25)
• Figure 37: Modality Reach Heat-Map - Respiratory Imaging AI Worldwide - 2024
• Figure 38: Markintel GTM Growth Maturity Framework - Orthopedic/MSK Imaging AI - World
• Figure 39: Regulatory Velocity - Orthopedic (MSK) Imaging AI Worldwide - (Mar '24 - Jun '25)
• Figure 40: Modality Reach Heat-Map - Orthopedic (MSK) AI
• Figure 41: Revenue Breakdown - "Other" Clinical Areas Imaging AI Worldwide (2024)
• Figure 42: Reimbursement Readiness Heatmap - Other Clinical Areas
• Figure 43: Other Clinical Areas Imaging AI Depth vs Breadth by Clinical Area
• Figure 44: Regulatory Velocity - Other Clinical Areas Imaging AI (Mar '24 - Jun '25)
• Figure 45: Markintel GTM Growth and Maturity Matrix - CT Imaging AI - World
• Figure 46: Regulatory Velocity for CT Imaging AI by Clinical Area
• Figure 47: Regulatory Velocity for CT Imaging AI by Region
• Figure 48: CT-Attach Rate by Region (2024)
• Figure 49: CT AI Revenue Split (Factory vs Retrofit) by Region
• Figure 50: Markintel GTM Growth and Maturity Matrix - MRI Imaging AI - World
• Figure 51: Regulatory Velocity (MRI-AI Clearances) by Region
• Figure 52: Regulatory Velocity (MRI-AI Clearances) by Clinical Area
• Figure 53: MRI AI-Attach Rate by Region (2024)
• Figure 54: Factory vs Retrofit Revenue Split (MRI AI, 2024)
• Figure 55: Markintel GTM Growth and Maturity Matrix - X-ray Imaging AI - World
• Figure 56: Regulatory Velocity - X-ray AI by Region
• Figure 57: Regulatory Velocity - X-ray AI by Clinical Area
• Figure 58: Attach-Rate by Region (X-ray AI, 2024)
• Figure 59: Factory vs Retrofit Revenue Split (X-ray AI, 2024)
• Figure 60: Markintel GTM Growth and Maturity Matrix - Ultrasound AI - World
• Figure 61: Ultrasound AI Regulatory Velocity by Region
• Figure 62: Ultrasound AI Regulatory Velocity by Clinical Area
• Figure 63: Ultrasound AI Attach-Rate by Region (2024)
• Figure 64: Ultrasound A Factory vs Retrofit Revenue Split (2024)
• Figure 65: Markintel GTM Growth and Maturity Matrix - Nuclear/PET imaging AI - World
• Figure 66: Markintel GTM Growth and Maturity Matrix - North America
• Figure 67: Regulatory Velocity - North America
• Figure 68: OEM AI Attach-Rate by Modality - North America
• Figure 69: Factory vs Retrofit - North America
• Figure 70: Markintel Growth Maturity Matrix - US & Canada
• Figure 71: Markintel Solution Adoption & Growth Matrix - US & Canada
• Figure 72: Markintel Ecosystem Collaboration Matrix - US & Canada
• Figure 73: GTM Readiness Radar - US
• Figure 74: Customer Tier Potential - US
• Figure 75: GTM Timeline (2025-2028) - US
• Figure 76: Regulatory x Funding Heatmap - US (2024)
• Figure 77: Dual-Layer Adjacency-Opportunity Radar - US (Post-2026)
• Figure 78: Whitespace Partner-Fit Matrix - US (2024-26)
• Figure 79: GTM Readiness Radar - Canada
• Figure 80: Market Potential by Customer Tier - Canada (2032)
• Figure 81: Regulatory Velocity by Company - Europe
• Figure 82: Markintel Growth Maturity Matrix - Europe
• Figure 83: Markintel(TM) Ecosystem Collaboration Matrix (ECM) - Europe
• Figure 84: Markintel Solution Adoption & Growth Matrix - Europe
• Figure 85: OEM AI Attach Rate - Europe (2024)
• Figure 86: AI Revenue Split - Factory vs Retrofit Attach -- Europe (2024)
• Figure 87: GTM Readiness Radar - Europe
• Figure 88: Potential by Customer Tier - Europe (2032)
• Figure 89: GTM Timeline (2025 -> 2028) - Europe
• Figure 90: Adjacency Opportunity Radar (2026+) - Europe
• Figure 91: Regulatory x Funding Heatmap - Europe (2024)
• Figure 92: AI Imaging Whitespace Matrix - Europe
• Figure 93: GTM Readiness Radar - Germany
• Figure 94: Projected Imaging AI Spend by Customer Tier - Germany (2032)
• Figure 95: GTM Timeline - Germany
• Figure 96: GTM Readiness Radar - What Counts Most in France
• Figure 97: GTM Timeline (2024 30) - France
• Figure 98: Spend Potential by Customer Tier - France (2032)
• Figure 99: GTM Readiness Radar - UK
• Figure 100: Spend Potential by Customer Tier - UK (2032)
• Figure 101: GTM Timeline (2024 29) - UK
• Figure 102: Tiered Customer Landscape & Spend Potential (2032)
• Figure 103: GTM Readiness Radar - Italy
• Figure 104: GTM Timeline (2024-29) - Italy
• Figure 105: GTM Readiness Radar - Spain
• Figure 106: Tiered Customer Landscape - Spain
• Figure 107: GTM Timeline - Spain (2024-2029)
• Figure 108: GTM at a Glance - Rest of Europe (ROE)
• Figure 109: Tiered Customer Landscape - ROE (2032)
• Figure 110: GTM Timeline - ROE
• Figure 111: Regulatory Funding Heatmap (ROE Clusters)
• Figure 112: Markintel GTM Growth and Maturity Matrix - APAC
• Figure 113: Regulatory Velocity - APAC
• Figure 114: OEM AI Attach Rate - APAC
• Figure 115: AI Revenue Split - Factory vs Retrofi t - APAC
• Figure 116: GTM Readiness Radar - APAC
• Figure 117: Tiered Customer Landscape - APAC (2032)
• Figure 118: GTM Timeline - APAC (2024-29)
• Figure 119: Regulatory Funding Heatmap - APAC
• Figure 120: Markintel Growth Maturity Matrix - China AI in Medical Imaging
• Figure 121: Markintel Ecosystem Collaboration Matrix - China
• Figure 122: Markintel Solution Adoption and Growth Matrix - China
• Figure 123: GTM Readiness Radar - China
• Figure 124: Tiered Customer Landscape - China (2032)
• Figure 125: GTM Timeline - China (2024-29)
• Figure 126: Adjacency-Opportunity Radar - China
• Figure 127: Regulatory Funding Heatmap - China
• Figure 128: Markintel Solution Adoption & Growth Matrix - Japan
• Figure 129: Markintel Ecosystem Collaboration Matrix - Japan
• Figure 130: GTM Readiness Radar - Japan
• Figure 131: GTM Timeline - Japan
• Figure 132: Adjacency Opportunity Radar - Japan
• Figure 133: Regulatory Funding Heatmap - Japan
• Figure 134: White Space Partnership Matrix - Japan
• Figure 135: Markintel Solution Adoption & Growth Matrix - India
• Figure 136: Markintel Ecosystem Collaboration Matrix - India
• Figure 137: GTM Readiness Radar - India
• Figure 138: Tiered Customer Landscape - India
• Figure 139: GTM Timeline - India
• Figure 140: Adjacency-Opportunity Radar - India
• Figure 141: Regulatory x Funding Heatmap - India
• Figure 142: Six-Pillar GTM Readiness Radar - South Korea
• Figure 143: Tiered Customer Landscape - South Korea
• Figure 144: Five-Step GTM Timeline - South Korea
• Figure 145: Adjacency-Opportunity Radar - South Korea
• Figure 146: Regulatory x Funding Heatmap - South Korea
• Figure 147: GTM Readiness Radar - Australia
• Figure 148: GTM Timeline - Australia
• Figure 149: Adjacency-Opportunity Radar - Australia
• Figure 150: Regulatory x Funding Heatmap
• Figure 151: GTM Readiness Heatmap - ROAPAC Clusters
• Figure 152: Five-Step GTM Roll Out Timeline (2024 2029) - ROAPAC
• Figure 153: Growth Driver Waterfall - LATAM
• Figure 154: Markintel Solution Adoption & Growth Matrix - LATAM
• Figure 155: Markintel Ecosystem Collaboration Matrix - LATAM
• Figure 156: GTM Readiness Radar - LATAM
• Figure 157: GTM Timeline - LATAM
• Figure 158: Cluster-Priority Heatmap
• Figure 159: Regulatory Velocity & Reimbursement Pulse - LATAM
• Figure 160: OEM AI Attach Rate - LATAM
• Figure 161: Markintel Solution Adoption & Growth Matrix - MEA
• Figure 162: Markintel Ecosystem Collaboration Matrix - MEA
• Figure 163: GTM Readiness Radar - MEA
• Figure 164: Country Cluster Heatmap - MEA
• Figure 165: GTM Timeline - Pilot to Scale (2024-2029) - MEA
• Figure 166: Adjacency-Opportunity Radar - MEA
• Figure 167: Regulatory Velocity - MEA
• Figure 168: Attach Rate Trends - MEA

List of Tables

• Table 1: World Market for AI in Medical Imaging by Geographic Region (2023-2032, USD Million)
• Table 2: World Market for AI in Medical Imaging by Clinical Area (2023-2032, USD Million)
• Table 3: World Market for AI in Oncology Imaging by Region (2023-2032, USD Million)
• Table 4: World Market for AI in Cardiology Imaging by Region (2023-2032, USD Million)
• Table 5: World Market for AI in Neurology Imaging by Region (2023-2032, USD Million)
• Table 6: World Market for AI in Respiratory Imaging by Region (2023-2032, USD Million)
• Table 7: World Market for AI in Orthopedic/MSK Imaging by Region (2023-2032, USD Million)
• Table 8: World Market for AI in Imaging for Other Clinical Areas by Region (2023-2032, USD Million)
• Table 9: World Market for AI in Medical Imaging by Modality (2023-2032, USD Million)
• Table 10: World Market for CT Modality AI (2023-2032, USD Million)
• Table 11: World Market for MRI Modality AI (2023-2032, USD Million)
• Table 12: World Market for X-ray Modality AI (2023-2032, USD Million)
• Table 13: World Market for Ultrasound Modality AI (2023-2032, USD Million)
• Table 14: World Market for Nuclear/PET Modality AI (2023-2032, USD Million)
• Table 15: World Market for AI in Medical Imaging by Revenue Stream (2023-2032, USD Million)
• Table 16: World Market for AI in Medical Imaging by Clinical Application (2023-2032, USD Million)
• Table 17: World Market for AI in Medical Imaging by End-Use Org (2023-2032, USD Million)
• Table 18: World Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
• Table 19: AI Imaging Market by Country - North America (2023-2032, USD Mill)
• Table 20: US Market for AI in Medical Imaging by Clinical Area (2023-2032, USD Million)
• Table 21: US Market for AI in Medical Imaging by Modality (2023-2032, USD Million)
• Table 22: US Market for AI in Medical Imaging by Revenue Stream (2023-2032, USD Million)
• Table 23: US Market for AI in Medical Imaging by Clinical Application (2023-2032, USD Million)
• Table 24: US Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
• Table 25: US Market for AI in Medical Imaging by AI Technology (2023-2032, USD Mill)
• Table 26: Canadian Market by Clinical Area (2023-2032, USD Million)
• Table 27: Canadian Market by Imaging Modality (2023-2032, USD Million)
• Table 28: Canadian Market by Revenue Stream (2023-2032, USD Million)
• Table 29: Canadian Market by Clinical Application (2023-2032, USD Million)
• Table 30: Canadian Market by End-Use Organization (2023-2032, USD Million)
• Table 31: Canadian Market by AI Technology (2023-2032, USD Million)
• Table 32: AI Imaging Market by Country - Europe (2023-2032, USD Mill)
• Table 33: German Market for AI in Medical Imaging by Clinical Area (2023-2032, USD Million)
• Table 34: German Market for AI in Medical Imaging by Modality (2023-2032, USD Million)
• Table 35: German Market for AI in Medical Imaging by Revenue Stream (2023-2032, USD Million)
• Table 36: German Market for AI in Medical Imaging by Clinical Application (2023-2032, USD Million)
• Table 37: German Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
• Table 38: German Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
• Table 39: French Market for AI in Medical Imaging by Clinical Area (2023-2032, USD Million)
• Table 40: French Market for AI in Medical Imaging by Modality (2023-2032, USD Million)
• Table 41: French Market for AI in Medical Imaging by Revenue Stream (2023-2032, USD Million)
• Table 42: French Market for AI in Medical Imaging by Clinical Application (2023-2032, USD Million)
• Table 43: French Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
• Table 44: French Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
• Table 45: UK Market for AI in Medical Imaging by Clinical Area (2023-2032, USD Million)
• Table 46: UK Market for AI in Medical Imaging by Modality (2023-2032, USD Million)
• Table 47: UK Market for AI in Medical Imaging by Revenue Stream (2023-2032, USD Million)
• Table 48: UK Market for AI in Medical Imaging by Clinical Application (2023-2032, USD Million)
• Table 49: UK Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
• Table 50: UK Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
• Table 51: Italian Market for AI in Medical Imaging by Clinical Area (2023-2032, USD Million)
• Table 52: Italian Market for AI in Medical Imaging by Modality (2023-2032, USD Million)
• Table 53: Italian Market for AI in Medical Imaging by Revenue Stream (2023-2032, USD Million)
• Table 54: Italian Market for AI in Medical Imaging by Clinical Application (2023-2032, USD Million)
• Table 55: Italian Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
• Table 56: Italian Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
• Table 57: GTM Readiness Radar - Italy
• Table 58: Spanish Market for AI in Medical Imaging by Clinical Area (2023-2032, USD Million)
• Table 59: Spanish Market for AI in Medical Imaging by Modality (2023-2032, USD Million)
• Table 60: Spanish Market for AI in Medical Imaging by Clinical Application (2023-2032, USD Million)
• Table 61: Spanish Market for AI in Medical Imaging by Revenue Stream (2023-2032, USD Million)
• Table 62: Spanish Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
• Table 63: Spanish Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
• Table 64: Rest of Europe Market for AI in Medical Imaging by Clinical Area (2023-2032, USD Million)
• Table 65: Rest of Europe Market for AI in Medical Imaging by Modality (2023-2032, USD Million)
• Table 66: Rest of Europe Market for AI in Medical Imaging by Revenue Stream (2023-2032, USD Million)
• Table 67: Rest of Europe Market for AI in Medical Imaging by Clinical Application (2023-2032, USD Million)
• Table 68: Rest of Europe Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
• Table 69: Rest of Europe Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
• Table 70: Adjacency-Opportunity Matrix - ROE (2026-2030)
• Table 71: White-Space Partnership Matrix - ROE
• Table 72: AI Imaging Market by Country - APAC (2023-2032, USD Mill)
• Table 73: Adjacency Opportunity Matrix - APACAdjacency Opportunity Matrix - APAC
• Table 74: Country-Cluster Framework - APAC
• Table 75: White Space Partner Framework - APAC
• Table 76: Channel x Pricing Matrix - APAC
• Table 77: Chinese Market by Clinical Area (2023-2032, USD Million)
• Table 78: Chinese Market by Modality (2023-2032, USD Million)
• Table 79: Chinese Market by Revenue Stream (2023-2032, USD Million)
• Table 80: Chinese Market by Clinical Application (2023-2032, USD Million)
• Table 81; Chinese Market by End-Use Organization (2023-2032, USD Million)
• Table 82: Chinese Market by AI Technology (2023-2032, USD Million)
• Table 83: Japanese Market by Clinical Area (2023-2032, USD Million)
• Table 84: Japanese Market by Modality (2023-2032, USD Million)
• Table 85: Japanese Market by Revenue Stream (2023-2032, USD Million)
• Table 86: Japanese Market by Clinical Application (2023-2032, USD Million)
• Table 87: Japanese Market by End-Use Organization (2023-2032, USD Million)
• Table 88: Japanese Market by AI Technology (2023-2032, USD Million)
• Table 89: Indian Market by Clinical Area (2023-2032, USD Million)
• Table 90: Indian Market by Modality (2023-2032, USD Million)
• Table 91: Indian Market by Revenue Stream (2023-2032, USD Million)
• Table 92: Indian Market by Clinical Application (2023-2032, USD Million)
• Table 93: Indian Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
• Table 94: Indian Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
• Table 95: South Korean Market by Clinical Area (2023-2032, USD Million)
• Table 96: South Korean Market by Modality (2023-2032, USD Million)
• Table 97: South Korean Market by Revenue Stream (2023-2032, USD Million)
• Table 98: South Korean Market by Clinical Application (2023-2032, USD Million)
• Table 99: South Korean Market End-Use Organization Type (2023-2032, USD Million)
• Table 100: South Korean Market by AI Technology (2023-2032, USD Million)
• Table 101: Australian Market by Clinical Area (2023-2032, USD Million)
• Table 102: Australian Market by Modality (2023-2032, USD Million)
• Table 103: Australian Market by Revenue Stream (2023-2032, USD Million)
• Table 104:Australian Market by Clinical Application (2023-2032, USD Million)
• Table 105: Australian Market by End-Use Organization (2023-2032, USD Million)
• Table 106: Australian Market by AI Technology (2023-2032, USD Million)
• Table 107: Rest of Asia-Pacific (ROAPAC) Market by Clinical Area (2023-2032, USD Million)
• Table 108: Rest of Asia-Pacific (ROAPAC) Market by Modality (2023-2032, USD Million)
• Table 109: Rest of Asia-Pacific (ROAPAC) Market by Revenue Stream (2023-2032, USD Million)
• Table 110: Rest of Asia-Pacific (ROAPAC) Market by Clinical Application (2023-2032, USD Million)
• Table 111: Rest of Asia-Pacific (ROAPAC) Market by End-Use Organization (2023-2032, USD Million)
• Table 112: Rest of Asia-Pacific (ROAPAC) Market by AI Technology (2023-2032, USD Million)
• Table 113: Latin American (LATAM) Market by Clinical Area (2023-2032, USD Million)
• Table 114: Latin American (LATAM) Market by Modality (2023-2032, USD Million)
• Table 115: Latin American (LATAM) Market by Revenue Stream (2023-2032, USD Million)
• Table 116: Latin American (LATAM) Market by Clinical Application (2023-2032, USD Million)
• Table 117: Latin American (LATAM) Market by End-Use Organization (2023-2032, USD Million)
• Table 118: Latin American (LATAM) Market by AI Technology (2023-2032, USD Million)
• Table 119: Middle East and African (MEA) Market by Clinical Area (2023-2032, USD Million)
• Table 120: Middle East and African (MEA) Market by Modality (2023-2032, USD Million)
• Table 121: Middle East and African (MEA) Market by Revenue Stream (2023-2032, USD Million)
• Table 122: Middle East and African (MEA) Market by Clinical Application (2023-2032, USD Million)
• Table 123: Middle East and African (MEA) Market by End-Use Organization (2023-2032, USD Million)
• Table 124: Middle East (MEA) Market AI Technology (2023-2032, USD Million)

Volume Two - Company Briefs

Company Briefs Research Methodology

1. Methodology At a Glance

2. Scope & Inclusion Logic

3. Research Inputs

4. Analytical Workflow

5. Frameworks & Proprietary Tools

6. Financial Modeling Assumptions

7. Quality Assurance & Governance

8. Limitations

9. How to Interpret the Company Briefs

1. 4D Medical Ltd.

• 1. Company Overview
• 2. Technology & AI-Imaging Portfolio
• 3. Go-to-Market & Partnerships
• 4. Regulatory & Reimbursement Status
• 5. Financial Pulse & Scale Indicators
  • 5.1. Commercial Ramp (Revenue & Site Expansion)
  • 5.2. Revenue Allocation
  • 5.3. Marketstrat Insight -- Economics at a Glance
• 6. Competitive Positioning
• 7. Growth vs. GTM Maturity
• 8. Strategic Outlook & Watch-Items

2. Accuray Inc.

• 1. Company Overview
• 2. Technology & AI-Imaging Portfolio
• 3. Go-to-Market & Partnerships
• 4. Regulatory & Reimbursement Status
• 5. Financial Pulse & Scale Indicators
• 6. Marketstrat Insight -- ClearRT Upgrade Attach-Rate Economics
• 7. Competitive Positioning
• 8. Segment Scores (Heat-Map)
• 9. Strategic Outlook & Watch-Items

3. Adiposs SA

• 1. Company Overview
• 2. Technology & Product Portfolio
• 3. Go-to-Market & Partnerships
• 4. Regulatory & Evidence Roadmap
• 5. Financial Pulse & Scale Indicators
  • 5.1. Marketstrat Insight - ImageBAT Attach-Rate Value Unlock
• 6. Funding History and ImageBAT Development Pipeline
• 7. Competitive Positioning
• 7. Segment Scores (1 = Low, 5 = High)
• 9. Strategic Outlook & Watch-Items

4. Advanced Micro Devices (AMD)

• 1. Strategic Context
• 2. Platform-Leverage Matrix
• 3. Current Healthcare/Imaging Engagements
• 4. Latest Performance & Financial Signals
• 5. Competitive Lens vs. Other Tech Heavyweights
• 6. Data Center/AI Revenues
• 7. AI GPU Roadmap Timeline
• 8. Near-Term Watch-List

5. Agfa HealthCare

• 1. Company Overview
• 2. Platform-Leverage Matrix and Scorecard
• 3. Latest Releases & Partnerships (2025)
• 4. Financial Pulse & KPIs
• 5. Revenue and Cloud Mix Trajectory
• Marketstrat Insight -- Cloud-EI Conversion Uplift
• 6. Deal Momentum (Cloud-EI) Milestone Pipeline
• 7. Competitive Position vs Imaging-IT Peers
• 8. Platform Watch-Items (2025-26)

6. Aidoc

• 1. Company Overview
• 2. Technology, Portfolio, and Platform Leverage
• 3. Regulatory Velocity
• 3. Go-to-Market & Growth Signals
• 4. Growth & Maturity Heatmap
• 5. Financial Pulse
• 6. Marketstrat Insight -- Multi-Module Expansion Uplift
• 7. Revenue & Installed Base Growth
• 8. Competitive Positioning
• 9. Strategic Watch-Items 2025-26

7. AIQ Solutions

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Oncology-Trial Upsell Dividend
• 9. Marketstrat Take & Watch-Items

8. Airdoc

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Sales vs Screening Sites
• 8. Marketstrat Insight - Insurance-Channel Upsell Dividend
• 9. Marketstrat Take & Watch-Items

9. Annalise.ai

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Cross-Modality Attach Dividend
• 9. Take & Watch-Items

10. Align X-ray Insights

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage Heatmap
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - Invisalign Channel Upsell
• 8. Marketstrat Take & Watch-Items

11. Artrya

• 1. Company Overview
• 2. Platform & Portfolio
• 3. Go-to-Market & Partnerships
• 4. Regulatory Velocity & Evidence Roadmap
• 5. Growth & Maturity Scores (Marketstrat rubric)
• 6. Financial Pulse
  • 6.1. Revenue & Cash Burn Trajectory
• 7. Marketstrat Insight - CCTA Attach-Rate & Avoided Cath Savings
• 8. Competitive Lens
• 9. Strategic Watch-Items

12. Astute Imaging

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage Heatmap
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Structural-Heart Planning Upside
• 8. Marketstrat Take & Watch-Items

13. Avicenna.ai

• 1. Company Overview
• 2. Technology & Portfolio
• 3. Go-to-Market & Partnerships
• 4. Regulatory Velocity & Evidence Roadmap
• 5. Growth & Maturity Scores (Markintel rubric)
• 6. Financial Pulse (Euro)
• 7. Marketstrat Insight - Triage-Suite Upsell Economics
• 8. Revenue Growth vs Installed Base
• 9. Competitive Snapshot

10. Strategic Watch-Items

14. AZmed

• 1. Company Overview
• 2. Technology & Portfolio
• 3. Go-to-Market & Partnerships
• 4. Regulatory Velocity & Evidence Roadmap
• 5. Growth & Maturity Scores (Markintel rubric)
• 6. Financial Pulse
  • 6.1. Revenue and Site Growth Trajectory
• 7. Marketstrat Insight - Missed-Fracture Litigation-Risk Offset
• 8. Competitive Lens
• 9. Strategic Watch-Items

15. Baidu

• 1. Company Overview
• 2. Platform-Leverage Score and Matrix
• 3. Go-to-Market Highlights (2024-25)
• 4. Financial Pulse
  • 4.1. AI Cloud vs. Healthcare Revenue Trajectory
• 5. Marketstrat Insight - Tier-2/3 CT-AI Cloud Attach-Rate
• 6. Growth & Maturity Scores
• 7. China Market Footprint & Policy Tailwinds
• 8. China Competitive Landscape (Imaging-AI Platforms)
• 9. Imaging AI Regulatory Path

10. Strategic Watch-Items (China)

16. Bayer Radiology

• 1. Company Overview
• 2. Radiology Portfolio
• 3. AI Regulatory Milestones
• 4. Go-to-Market & Partnerships
• 5. Financial Pulse
  • 5.1. Revenue Mix Trajectory
• 6. Marketstrat Insight - Calantic Adoption in U.S. Comprehensive Stroke Centers
• 7. Growth & Maturity Scores (Markintel Rubric)
• 8. Marketstrat Take - Strategic Watch-Items
• 9. Calantic-Blackford Architecture & Strategic Fit

10. Platform Leverage

11. Quantified Synergy Outlook (internal Bayer targets)

12. Ecosystem Implications

17. BioMind

• 1. Company Overview
• 2. AI-Imaging Portfolio and Platform Leverage
• 3. Go-to-Market & Partnerships
• 4. Growth & Maturity Scores
• 5. Regulatory Velocity & Reimbursement Status
• 6. Competitive Positioning
• 7. Financial Pulse (unaudited)
• 8. Marketstrat Insight - Grade-3A Neuro-Center Attach-Rate
• 9. Strategic Outlook & Watch-Items

18. Blackford Analysis Ltd.

• 1. Company Overview
• 2. Platform & Portfolio
  • 2.1. Platform Leverage - Bayer
• 3. Go-to-Market & Channels (2024-25 refresh)
• 4. Regulatory & Evidence Snapshot
• 5. Growth & Maturity Scores (Marketstrat rubric)
• 6. Financial Pulse
  • 6.1. Revenue vs Installed Base Growth
• 7. Marketstrat Insight - AI-Marketplace Revenue-Share Uplift
• 8. Strategic Watch-Items 2025-26

19. Bracco Imaging S.p.A.

• 1. Company Overview
• 2. Portfolio at-a-Glance
  • 2.1. Platform Leverage - Bracco
• 3. Go-to-Market & Partnerships (2024-25)
• 4. Regulatory & Evidence Highlights
• 5. Growth & Maturity Scores (Markintel Rubric)
• 6. Financial Pulse (Radiology)
  • 6.1. Shift Toward Digital Revenue
• 7. Marketstrat Insight - SmartInject AI Attach-Rate Uplift (Bracco)
• 8. Marketstrat Watch-Items

20. Brainlab AG

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Revenue vs OR Installs
• 8. Marketstrat Insight - Mixed-Reality Attach Dividend
• 9. Marketstrat Take & Watch-Items

21. Brainomix Ltd.

• 1. Company Overview
• 2. Product Portfolio
  • 2.1. Platform Leverage - Brainomix
• 3. Go-to-Market & Partnerships
• 4. Regulatory Velocity
• 5. Growth & Maturity Scores (Markintel rubric)
• 6. Financial Pulse
  • 6.1. Revenue & Installed Base - Brainomix
• 7. Marketstrat Insight - Stroke-Center Attach-Rate Uplift (Brainomix Ltd)
• 8. Strategic Watch-Items

22. BrightHeart.ai

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Regulatory/Dev Timeline
• 7. Financial Pulse (estimate)
• 8. Marketstrat Insight - Operator-Independence Flywheel

23. Butterfly Network, Inc. (NYSE: BFLY)

• 1. Company Overview
• 2. AI-Imaging Portfolio
  • 2.1. Platform Leverage - Butterfly Network
• 3. Go-to-Market & Partnerships
• 4. Regulatory & Reimbursement Status
  • 4.1. Regulatory Velocity - Butterfly Network
• 5. Growth & Maturity Scores (Markintel Rubric)
• 6. Competitive Positioning
• 7. Financial Pulse.
• 8. Marketstrat Insight - AI-Add-On Attach-Rate Uplift (Butterfly Network)
• 9. Strategic Outlook & Watch-Items.

24. CancerCenter.ai

• 1. Company Overview
• 2. Platform & Portfolio
  • 2.1. Platform Leverage - CancerCenter.ai
• 3. Go-to-Market & Partnerships
• 4. Regulatory & Evidence Status
• 5. Growth & Maturity Scores (Markintel rubric)
• 6. Financial Pulse (unaudited)
• 7. Growth & Maturity Scores
• 8. Competitive Lens (oncology digital-pathology cohort)
• 9. Strategic Watch-Items 2025-26

25. Canon Medical Systems

• 1. Company Overview
• 2. AI-Imaging Portfolio
  • 2.1. Platform Leverage - Canon
• 3. Go-to-Market & Partnerships
• 4. Regulatory & Evidence Pulse
• 5. Competitive Positioning - Deep-Learning CT Reconstruction
  • 5.1. Key Takeaways for Canon Medical
• 6. Financial Pulse
  • 6.1. Revenue and Margin Trend - Canon
• 7. Growth & Maturity Scores (Markintel Rubric) - Canon
• 8. Marketstrat Insight - AiCE Upgrade Attach-Rate Economics (Canon Medical)
• 9. Strategic Outlook & Watch-Items

26. Carestream

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Panel Shipments
• 8. Marketstrat Insight - Smart Noise Cancellation Attach Dividend
• 9. Marketstrat Take & Watch-Items

27. Caristo Diagnostics

• 1. Company Overview
• 2. AI-Imaging Portfolio
  • 2.1. Platform Leverage
• 3. Go-to-Market & Partnerships
• 4. Growth & Maturity Scores
• 5. Regulatory & Evidence Pulse
  • 5.1. Regulatory Velocity Timeline
• 5. Competitive Positioning
• 6. Financial Pulse
• 7. Marketstrat Insight - CaRi-Heart(TM) Attach-Rate to U.S. Coronary CTA (Caristo Diagnostics)
• 8. Strategic Outlook & Watch-Items

28. CARPL.ai

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Marketplace Commission Dividend
• 9. Marketstrat Take & Watch-Items

29. CathWorks

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Cath-Labs
• 8. Marketstrat Insight - Medtronic Attach-Rate Dividend
• 9. Marketstrat Take & Watch-Items

30. Cellmatiq GmbH

• 1. Company Overview
• 2. Portfolio & Differentiation
• 3. GTM and Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores (Markintel rubric)
• 6. Financial Pulse (unaudited)
• 7. Marketstrat Insight - Radiologist / Ortho Throughput Uplift
• 8. Marketstrat Take & Watch Watch-Items

31. Cerebra AI

• 1. Company Overview
• 2. Product & Pipeline
  • 2.1. Platform Leverage - Cerebra AI
• 3. Go-to-Market
• 4. Regulatory & Evidence Ladder
• 5. Growth & Maturity Scores (Markintel rubric)
• 6. Financial Pulse (unaudited)
• 7. Marketstrat Insight - Financing Runway Gauge (CerebraAI)
• 8. Strategic Watch-Items

32. Clarius Mobile Health

• 1. Company Overview
• 2. AI-Imaging Portfolio
  • 2.1. Platform Leverage - Clarius Mobile Health
• 3. Go-to-Market & Partnerships
• 4. Regulatory & Reimbursement Pulse
• 5. Competitive Positioning
• 6. Financial Pulse
  • 6.1. Revenue Trajectory & SaaS Mix
• 7. Growth & Maturity
• 8. Marketstrat Insight - AI Cloud Membership ARPU Uplift (Clarius Mobile Health)
• 9. Strategic Outlook & Watch-Items

33. Cleerly

• 1. Company Overview
• 2. Portfolio Snapshot
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
  • 4.1. Regulatory Velocity
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - AI-QTrack Longitudinal Upsell (Cleerly)
• 8. Marketstrat Take & Watch-Items

34. Combinostics Oy

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Cross-Modality Attach Dividend
• 9. Marketstrat Take & Watch-Items

35. ContextFlow GmbH

• 1. Company Overview
• 2. Portfolio & Innovation
  • 2.1. Platform Leverage
• 3. Go-to-Market & Partnerships
• 4. Regulatory & Evidence Status
• 5. Competitive Lens (Chest-CT cohort)
• 6. Financial Pulse (unaudited)
• 7. Growth & Maturity Scores
• 8. Competitor Landscape & Strategic Benchmarking
• 9. Business Model & Revenue Streams

10. Integrated Growth Canvas

11. Strategic Outlook & Key Challenges

12. Strategic Implications

36. CoreTechs Labs

• 1. Company Overview
• 2. Product Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Regulatory Velocity
• 7. Marketstrat Insight - Volumetric AI Penetration
• 8. Marketstrat Take & Watch-Items

37. CureMetrix

• 1. Company Overview
• 2. Product Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4.Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Mammography AI Triaging Penetration
• 8. Marketstrat Take & Watch-Items

38. deepc GmbH

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - NHS Trust Attach Dividend
• 9. Marketstrat Take & Watch-Items

39. DeepHealth (RadNet)

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. iCAD Acquisition Assessment & Outlook
  • 3.1. Why iCAD?
  • 3.2. Merger Rationale
• 4. GTM & Partnerships
• 5. Regulatory / Evidence
• 6. Growth & Maturity Scores
• 7. Financial Pulse
• 8. Marketstrat Insight - Genius-EBCD Attach-Rate Economics (FY-2025)
• 9. Take & Watch-Items

40. DeepMind (Google)

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Foundation-Model Licensing Uplift
• 8. Marketstrat Take & Watch-Items

41. DeepSight Technology

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage Heatmap
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - Deep-Penetration Ultrasound TAM Expansion
• 8. Marketstrat Take & Watch-Items

42. DeepTek.ai

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Genki TB Mobile-Van Dividend
• 9. Marketstrat Take & Watch-Items

43. DEEPNOID INC

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - M4CXR Generative-Report Dividend
• 9. Marketstrat Take & Watch-Items

44. Deepwise

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Breast-AI Upsell Dividend
• 9. Marketstrat Take & Watch-Items

45. Diagnocat

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - CBCT-AI Upsell Potential
• 8. Marketstrat Take & Watch-Items

46. Digital Diagnostics Inc

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Primary-Care Eye Exam Penetration
• 8. Marketstrat Take & Watch-Items

47. EchoNous

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - "3-Probe" Competitive Offset
• 8. Marketstrat Take & Watch-Items

48. Elucid BioImaging

• 1. Company Overview
• 2. Portfolio
• 3. GTM & Revenue Model
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Elucid/NTAP Adoption Scenarios
• 8. Marketstrat Take & Watch-Items

49. Enlitic

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage Heatmap
• 3. GTM & Partnerships
• 4. Regulatory / Evidence & Partnerships
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - OEM-Led ARR Flywheel
• 8. Marketstrat Take & Watch-Items

50. Envisionit Deep AI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Revenue Model
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - TB-Triage Expansion Scenarios
• 8. Marketstrat Take & Watch-Items

51. Exo Inc

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
  • 6.1. Revenue vs Installed Sites
• 7. Marketstrat Insight - Probe-to-Workflow Attach Dividend
• 8. Marketstrat Take & Watch-Items

52. Ferrum Health

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform-Leverage Strip
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Platform Penetration Scenarios
• 8. Marketstrat Take & Watch-Items

53. Fujifilm

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage Heatmap
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores and Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - AI Modality Upsell Flywheel
• 8. Marketstrat Take & Watch-Items

54. GE Healthcare

• 1. Company Overview
• 2. Segment & Competitor Map
  • 2.1. Segment Revenue Forecast
• 3. Product & AI Portfolio
  • 3.1. Platform Leverage
• 4. Regulatory & Reimbursement Grid
• 5. Growth & Maturity Scores
• 6. Revenue vs Installed Base
• 7. Financial Pulse
• 8. Marketstrat Insight - Edison AI Attach-Rate Scenarios
• 9. Tariff Sensitivity

10. Partnerships & Ecosystem

11. Supply-Chain & Ops Snapshot

12. Marketstrat Take & Watch-Items

55. Gleamer

• 1. Company Overview
• 2. Portfolio
• 3. GTM & Partnerships
• 4. Regulatory / Development Velocity
• 5. Growth & Maturity Scores
• 6. Platform-Leverage Strip
• 7. Financial Pulse & Multi-Product Attach Model
• 8. Marketstrat Insight - Multi-Product Attach Scenarios (2029)

10. Marketstrat Take & Watch-Items

56. Guerbet SA

• 1. Company Overview
• 2. Portfolio
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Platform-Leverage Strip
• 7. Financial Pulse (EUR)
• 8. Marketstrat Insight - AI Upsell on Contrast Accounts
• 9. Marketstrat Take & Watch-Items

57. Heartflow, Inc.

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Multi-Module Attach Scenarios (2029)
• 8. Marketstrat Take & Watch-Items

58. HeartFocus

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Task-Shift Echo Economics

59. Heuron

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Stroke-Suite Expansion Economics
• 8. Take & Watch-Items

60. Hologic Inc

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM Partnerships
• 4. Regulatory / Evidence
• 6. Financial Pulse
• 7. Deep Dive: Hologic's Breast & Skeletal Health Franchise
• 8. Marketstrat Insight - Genius AI Revenue Ramp to FY-2029
• 9. Marketstrat Takeaway and Watch Items

61. Huawei

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse (Healthcare & Imaging AI estimates)
• 7. Marketstrat Insight - "Optical-Edge Flywheel"
• 8. Marketstrat Take & Watch-Items

62. Huiyihuiying (HY Medical)

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse (est.)
• 7. Marketstrat Insight - Tier-2 Hospital Roll-out Economics
• 8. Marketstrat Take & Watch-Items

63. Hyperfine

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Portable MRI Flywheel
• 8. Marketstrat Take & Watch-Items

64. icometrix

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence Timeline
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - Neuro-Suite Upsell Flywheel
• 8. Marketstrat Take & Watch-Items

65. ImageBiopsy

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Knee-OA Surgical-Triage Upsell
• 9. Marketstrat Take & Watch-Items

66. Imagen Technologies

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform
• 3. GTM & Partnerships
• 4. Regulatory / Evidence Timeline
• 5. Growth & Maturity Scores
• 6. Financial Pulse (model)
• 7. Marketstrat Insight - Clinic-Attach Flywheel
• 8. Take & Watch-Items

67. Incepto Medical SAS

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Iberia Rollout Dividend
• 9. Marketstrat Take & Watch-Items

68. Infervision

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Cross-Suite Attach Dividend
• 9. Marketstrat Take & Watch-Items

69. JLK Inc

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse + Revenue vs Overseas Mix
• 7. Marketstrat Insight - Stroke-Suite Attach Dividend
• 8. Take & Watch-Items

70. Koios Medical

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage Strip
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - OEM-Bundle Upsell Dividend
• 9. Marketstrat Take & Watch-Items

71. Konica Minolta

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs DR/DDR Fleet
• 8. Marketstrat Insight - DDR Attach Dividend
• 9. Marketstrat Take & Watch-Items

72. LPIXEL

• 1. Company Overview
• 2. Portfolio
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - MENA JV Upsell Dividend
• 7. Marketstrat Take & Watch-Items

73. Lantheus Holdings

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Revenue vs PYLARIFY Dose Volume
• 8. Marketstrat Insight - PYLARIFY AI Attach Dividend
• 9. Marketstrat Take & Watch-Items

74. Lunit Inc.

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM Partnerships
• 4. Regulatory/Dev Timeline
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - Device-Attach Flywhee
• 8. Marketstrat Take & Watch Items

75. Mediaire GmbH

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - EU Neuro-MRI Upsell Flywheel
• 8. Marketstrat Take & Watch-Items

76. Median Technologies

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - ARR vs Attach Scenarios
• 8. Marketstrat Take & Watch Items

77. Medtronic PLC

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse (base metrics)
• 7. Marketstrat Insight - ARR vs Attach (Predictive-Rod)
• 8. Marketstrat Take & Watch-Items

78. Merative L.P.

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence Timeline
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse (Est)
• 7. Competitive Landscape - Enterprise Imaging & Data Platforms
  • 7.1. Where Merative Stands
• 8. Marketstrat Insight - Cloud-Migration License Flywheel
• 9. Marketstrat Take & Watch-Items

79. Microsoft

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Two Overlapping Competitive Arenas
• 8. Competitive Landscape Snapshot (Nuance PIN Focus)
• 9. Marketstrat Insight - FY-2029 Azure Imaging-Cloud ARR Scenarios

10. Marketstrat Take & Watch-Items

80. Mindray Ltd

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Strategic Deep Dive Highlights
• 7. Financial Pulse
  • 7.1. Marketstrat Insight - CT Entry P&L Impact vs Status-Quo
• 8. Marketstrat Insight - CT Hardware & ClariCT SaaS Scenarios
• 9. Marketstrat Take & Watch-Items

81. MSKai

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Prior-Auth Velocity Flywheel
• 8. Marketstrat Take & Watch-Items

82. Nanox Imaging Ltd.

• 1. Key Takeaways
• 2. Company Overview
• 3. Portfolio
  • 3.1. Platform-Leverage Strip
• 4. GTM & Partnerships
• 5. Regulatory / Evidence
• 6. Growth & Maturity Scores
• 7. Financial Pulse - Scenario View
• 8. Marketstrat Insight - ARR Scenario Analysis (FY-2027)
• 9. Strategic Insights & Outlook

10. Marketstrat Take & Watch-Items

83. Nico-Lab B.V.

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Hospitals
• 8. Marketstrat Insight - Network-Referral ARR Dividend
• 9. Marketstrat Take & Watch-Items

84. NIRAMAI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - PHC-Screening Hub Dividend
• 9. Marketstrat Take & Watch-Items

85. NVIDIA

• 1. Key Takeaways
• 2. Company Overview
• 3. Portfolio
  • 2.1. Platform Leverage
• 4. GTM & Partnerships
• 5. Regulatory / Evidence
  • 5.1. Reg-Velocity Benchmark - GPU / ASIC Footprints (Heatmap)
• 6. Growth & Maturity Scores
• 7. Financial Pulse
• 8. Marketstrat Insight - "Physical-AI TAM Uplift"
• 9. Take & Watch-Items

10. Strategic Insights & Outlook

86. Olea Medical

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Imaging Revenue vs Canon MR Shipments
• 8. Marketstrat Insight - Inline-Perfusion Upsell Dividend
• 9. Marketstrat Take & Watch-Items

87. Oracle

• 1. Key Takeaways
• 2. Company Overview
• 3. Portfolio
  • 3.1. Platform Leverage
• 4. GTM & Partnerships
• 5. Regulatory / Evidence
• 6. Growth & Maturity Scores
• 7. Financial Pulse
• 8. Marketstrat Insight - "PACS-to-Cloud Migration Elasticity"
• 9. Strategic Insights & Outlook

10. Marketstrat Take & Watch-Items

88. Oxipit

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Autonomous Reporting Dividend
• 9. Take & Watch-Items

89. Perimeter Medical Imaging

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Units
• 8. Marketstrat Insight - B-Series AI-Fee Dividend
• 9. Marketstrat Take & Watch-Items

90. Perspectum

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Multi-Organ Suite Attach Dividend
• 9. Marketstrat Take & Watch-Items

91. Philips Healthcare

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
  • 3.1. Pricing Models
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Photon-Counting Dividend
• 8. AI-Powered Imaging and Cloud Solutions
• 9. Marketstrat Take & Watch-Items

92. Pro Medicus, Ltd.

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - AI-Attach Flywheel
• 8. Marketstrat Take & Watch-Items

93. Qure.AI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - TB Program ROI (Health System Savings)
• 8. Marketstrat Insight-- AIRA Copilot ARR Lane
• 9. Strategic Insights & "Opportunistic" Takeaways

10. Marketstrat Watch-Items (12 mo)

94. Quibim

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse - FY-27 Growth Scenarios
• 7. Marketstrat Insight - Dual Upsell Dividend
• 8. Marketstrat Take & Watch-Items

95. Radiobiotics

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Hip-to-Knee Cross-Sell Dividend
• 9. Marketstrat Take & Watch-Items

96. Rad AI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Dual ARR Engine
• 8. Marketstrat Take & Watch-Items

97. RapidAI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - Angio-Suite ROI
• 8. Marketstrat Insight - Pulmonary Embolism Upsell
• 9. Marketstrat Take & Watch-Items

98. Samsung Healthcare

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - AI License Mix Dividend
• 8. Marketstrat Take & Watch-Items

99. ScreenPoint Medical

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - DBT-Upgrade Upsell Dividend
• 9. Marketstrat Take & Watch-Items

100. Segami Corporation

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Base
• 8. Marketstrat Insight - OASIS Thin Upsell Dividend
• 9. Marketstrat Take & Watch-Items

101. Shenzhen Keya Medical Technology Co., Ltd

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
• 7. Marketstrat Insight - CT-FFR Reimbursement Upside
• 8. Marketstrat Take & Watch-Items

102. Shukun Technology / Careverse

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - CT-FFR Upsell Dividend
• 9. Marketstrat Take & Watch-Items

103. Siemens Healthineers

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform-Leverage Strip
• 3. GTM & Partnerships
  • 3.1. Partnerships
  • 3.2. Pricing Models
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Strategic Differentiators
• 7. Financial Pulse
• 8. Marketstrat Insight - Photon-Counting Dividend
• 9. Marketstrat Take & Watch-Items

104. Sirona Medical

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heat-Map
• 6. Financial Pulse
• 7. Marketstrat Insight - Radiologist Time-Savings Dividend
• 8. Marketstrat Take & Watch-Items

105. Smart Soft Healthcare (CoLumbo)

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence Timeline
• 5. Growth & Maturity Heat-Map
• 6. Financial Pulse - Revenue vs Paying Sites
• 7. Marketstrat Insight - Reading-Time Dividend
• 8. Marketstrat Take & Watch-Items

106. Spectral AI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform-Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - Day-One Burn Triage Dividend
• 8. Marketstrat Take & Watch-Items

107. Stryker Corp

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heat-Map
• 6. Financial Pulse
  • 6.1. Revenue vs Installed Robots
• 7. Marketstrat Insight - Autonomous Nav License Dividend
• 8. Execution Outlook
• 9. Marketstrat Take & Watch-Items

108. Subtle Medical

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse - Revenue vs Active Licenses
• 7. Marketstrat Insight - Gadolinium-Dose Dividend
• 8. Execution Outlook (12-18 mos)
• 9. Marketstrat Take & Watch-Items

109. Synapsica

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - Motion X-ray Upsell Dividend
• 9. Execution Priorities (next 12 months)

10. Marketstrat Take

110. Tata Elxsi

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
  • 6.1. Revenue vs OEM Client Base
• 7. Marketstrat Insight - Royalty Flywheel Dividend
• 8. Stakeholder Voice Heatmap - AI Middleware Trust
• 9. Marketstrat Take & Execution Watchlist

111. Tempus AI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse - Revenue vs Active-Hospital Base
• 7. Marketstrat Insight - Arterys Cross-Sell Dividend, FY-28 Outlook)
• 8. Execution Dashboard (next 18 mo)
• 9. Marketstrat Take & Watch-Items

112. Tencent Holdings

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
  • 3.1. Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse - Revenue vs Installed Hospital Base
• 7. Marketstrat Insight - Cloud Paywall Flywheel Dividend
• 8. Marketstrat Take & Watch-Items

113. Therapixel

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Scores
• 6. Financial Pulse
  • 6.1. Revenue vs Installed-Site Base
• 7. Marketstrat Insight - EU AI-Second-Reader Dividend
• 8. Execution Signals to Watch
• 9. Marketstrat Take & Watch-Items

114. Ultromics

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 7. Revenue vs Installed Labs
• 8. Marketstrat Insight - HFpEF-Module Attach Dividend
• 9. Marketstrat Take & Watch-Items

115. United Imaging

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
  • 3.1. Partnerships & Ecosystem
  • 3.2. Competitive Benchmarking
  • 3.3. Tariff & Trade-Policy Impact
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
  • 6.1. Revenue vs Overseas Mix Forecast
  • 6.2. Geographic Expansion Outlook (2025-2027)
  • 6.3. Stakeholder-Voice Heat-Map
• 7. Marketstrat Insight - AI-Subscription Dividend
• 8. Marketstrat Take & Watch-Items

116. Us2.ai

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
  • 6.1. Revenue vs Installed-Base
• 7. Marketstrat Insight - Echo Everywhere
• 8. Marketstrat Take & Watch-Items

117. Vara AI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Development Timeline
• 5. Growth & Maturity Scores
• 6. Financial Pulse
  • 6.1. Revenue vs Screen-Exam Volume Forecast
• 7. Marketstrat Insight - AI-as-2nd-Reader Dividend (2028)

118. Vista AI

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Development Timeline
• 5. Growth & Maturity Scores
• 6. Financial Pulse
  • 6.1. Revenue vs Installed-Scanner Base Forecast
• 7. Marketstrat Insight - Cardiac-MRI Throughput Dividend (2027)
• 8. Marketstrat Take & Watch-Items

119. Viz.ai

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
  • 3.1. Partnership Spectrum
  • 3.2. Stakeholder Voice Heatmap
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Marketstrat Insight - Imaging Multi-Suite Attach-Rate Uplift 2027
• 8. Marketstrat Take & Watch-Items

120. VoxelCloud

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs Installed Sites
• 8. Marketstrat Insight - DermAI Consumer-Platform Dividend
• 9. Marketstrat Take & Watch-Items

121. VUNO

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
  • 6.1. Revenue vs Overseas Mix Forecast
• 7. Marketstrat Insight - Multi-Module Attach Dividend Scenarios
• 8. Marketstrat Take & Watch-Items

122. Zimmer Biomet

• 1. Company Overview
• 2. Portfolio
  • 2.1. Platform Leverage
• 3. GTM & Partnerships
• 4. Regulatory / Evidence
• 5. Growth & Maturity Heatmap
• 6. Financial Pulse
• 7. Revenue vs ROSA Installed Base
• 8. Marketstrat Insight - ROSA Shoulder Attach Dividend
• 9. Marketstrat Take & Watch-Items

관련자료